Biotin — sole-added-active oral product × Lower HbA1c in adults with type 2 diabetes

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Met	Full text not readStored summary read	N01 · Independent claimWhich biotin, population and HbA1c comparison does the question concern?Required (selected sole-added-biotin/HbA1c comparison)	The selected question asks whether oral biotin as the sole added active ingredient in adults with T2D lowers HbA1c at a prespecified follow-up compared with placebo, no supplement or usual care under identical background treatment. subclaims is an empty list. S01 S02 S04 S05 S10 S11 S15	This verifies the boundary; it does not establish efficacy or conclude that studies are absent worldwide.	Adults with T2D · Oral biotin as the sole addition · Comparator with identical background conditions · Between-group HbA1c result at a prespecified time point	For each source, compare the direct comparison results that match this question and the reasons for any mismatch.
2	Met	Full text not readStored summary read	N02 · Common treatmentDoes common metformin treatment exclude a comparison of a sole added ingredient?Required (selected sole-added-biotin/HbA1c comparison)	S11 is a candidate in which only biotin was added to the common treatment of metformin 500 mg/day in both arms, so it is not excluded because of concomitant treatment. The endpoint actually verified is not HbA1c. S11	This verifies the preservation of common-treatment information; it does not mean that an actual eligible HbA1c comparison has been obtained.	Background treatment in both arms, added ingredients, arm-specific changes/rescue treatment and the actual effect of interest	Compare results in which only biotin differs under identical background treatment, along with changes in diabetes medications.
3	Unverified	Full text not readStored summary read	N03 · Product identityAre the chemical form, origin and manufacturer of the directly eligible product known?Required (selected sole-added-biotin/HbA1c comparison)	exact_chemical_form and manufacturing_origin have null value entries/not_verified. source_part also leaves the chemical form, origin and manufacturer of the eligible preparation unverified. S01 S02 S04 S11 S15	The product identity for a directly eligible HbA1c comparison could not be verified. Products from other trials are not substituted.	Exact chemical form, origin, manufacturer and documentation verifying the active ingredient	Obtain and link the original product documentation and manufacturing specifications for the eligible result.
4	Unverified	Full text not readStored summary read	N04 · Formulation and qualityAre tablet/capsule form, excipients, brand, batch and purity verified?Required (selected sole-added-biotin/HbA1c comparison)	tablet_or_capsule, excipients, brand and batch_purity all have null values/not_verified. An oral product with a sole active ingredient is the question boundary, not the specifications of an actual eligible product. S01 S02 S04 S11 S15	Beyond the shared ingredient name, no direct information on formulation, excipients or quality is available.	Formulation, excipients, brand, batch/purity and other added active ingredients	Compare the preparation specifications and batch documentation for the eligible comparison.
5	Unverified	Full text not readStored summary read	N05 · DoseWhat are the eligible biotin dose, frequency and total exposure?Required (selected sole-added-biotin/HbA1c comparison)	dose, frequency, dietary_biotin and concurrent_supplements have null values/not_verified for the directly eligible comparison. S11's 5 mg 2 times daily is the exposure in a candidate study of another endpoint. S01 S02 S05 S06 S11	The eligible dose was not inferred from S11, chromium-combination products or assay-interference materials.	Eligible dose/frequency, dietary biotin, concurrent supplements and actual exposure	Link the relevant product, dose, frequency and dietary/supplement records to the eligible result.
6	Unverified	Full text not readStored summary read	N06 · Duration and follow-upHave the treatment duration and HbA1c follow-up time been specified?Required (selected sole-added-biotin/HbA1c comparison)	treatment_duration and followup_time have null values/not_verified. S11 used 4 weeks of biotin treatment followed by 2 weeks of observation off biotin, while S05 used a combination product for 90 days; neither fills in the eligible HbA1c duration. S05 S11	The eligible duration and time point are unverified; this is not a conclusion that the treatment has no effect because its duration is short or long.	Actual treatment duration, prespecified follow-up time and separate post-discontinuation time point	Compare the direct comparison's plan, treatment duration and results at each follow-up time point together.
7	Unverified	Full text not readStored summary read	N07 · Actual populationAre confirmed T2D diagnosis, baseline HbA1c and disease duration verified?Required (selected sole-added-biotin/HbA1c comparison)	The question concerns adults with T2D, but diagnostic_criteria, baseline_HbA1c and disease_duration have null values for the directly eligible comparison. Materials on other populations are retained, with direct attribution restricted. S01 S02 S04 S10 S11	An adjacent study recording baseline glycated hemoglobin is distinct from the target direct follow-up HbA1c comparison.	Diagnostic criteria, age, baseline HbA1c, disease duration and population composition	Compare recruitment, diagnosis, baseline tables and population composition for the eligible result.
8	Partly verified	Full text not readStored summary read	N08 · Biotin statusHave observations of low biotin been recast as confirmed deficiency correction?Required (selected sole-added-biotin/HbA1c comparison)	baseline_biotin and deficiency_assay have null values for the eligible comparison. The original KO explicitly states that observations of low circulating biotin were not recast as a trial treating confirmed deficiency. S01 S02 S04	The exclusion/inclusion boundaries were preserved, but the biotin status of the actual eligible population remains unverified.	baseline_biotin, deficiency_assay, deficiency definition and eligible status	Link the deficiency definition/assay to the direct HbA1c results for each relevant population.
9	Met	Full text not readStored summary read	N09 · Endpoint definitionWere between-group HbA1c changes distinguished from other glycemic outcomes?Required (selected sole-added-biotin/HbA1c comparison)	Priority is given to the between-group HbA1c change difference (%p), and an appropriately adjusted between-group endpoint contrast is separate. The original crux/content block and facets rule out substitution with FPG, PPG or other metabolic markers. S01 S02 S04 S11	This verifies the endpoint boundary; it does not mean that a direct estimate has been obtained.	Prespecified between-group HbA1c change difference in %p, adjusted endpoint contrast and measurement/analysis definitions	Compare the original plan with the change/endpoint estimates in the actual HbA1c tables.
10	Unverified	Full text not readStored summary read	N10 · Measurement methodAre the HbA1c assay method and red-cell-related factors verified?Required (selected sole-added-biotin/HbA1c comparison)	HbA1c_assay, HbA1c_interference, anemia_RBC_lifespan, transfusion_hemoglobin_variant and renal_function have null values/not_verified. S01 S02 S04 S06 S07 S11	Interference in the assay itself or between-arm differences in anemia could not be verified within the scope of the retained materials in this review.	HbA1c assay, interference, anemia/RBC lifespan, transfusion/Hb variants and renal function	Compare the assay principles, validation materials and baseline hematological/renal records for the eligible result.
11	Unverified	Full text not readStored summary read	N11 · Direct resultIs there an eligible between-group HbA1c estimate for biotin alone?Required (selected sole-added-biotin/HbA1c comparison)	between_group_effect, P and CI have null values for the directly eligible comparison. The assessment's direct_eligible_human_result_verified=false is a bounded gate for the fixed question. related_human_studies_exist=true is also retained. S01 S02 S04 S05 S11 S15	Positive combination-product and FPG results are not substituted, and null values are not converted to 0.	Directly eligible between-group HbA1c effect, follow-up time point, denominator and original result location	Verify the between-group effect and its definition/time point in the eligible original result.
12	Unverified	Full text not readStored summary read	N12 · Intervals and importanceCan the effect magnitude be interpreted using CI, P and MCID?Required (selected sole-added-biotin/HbA1c comparison)	CI, P and MCID all have null values/not_verified for the eligible HbA1c comparison. P=.03 for the chromium-combination product is not used to construct an interval or importance assessment for biotin alone. S05	This is nonverification of the source data, not evidence of an unimportant effect, a definitive finding of imprecision or evidence of equivalence.	Direct effect, confidence interval, variance, denominator and justified importance threshold	Compare the direct result's estimate, CI and basis for the MCID together.
13	Unverified	Full text not readStored summary read	N13 · Denominators and analysisAre the allocation, completion, analysis and ITT/PP denominators linked?Required (selected sole-added-biotin/HbA1c comparison)	randomized_n, completed_n, analysis_n and ITT_PP have null values for the directly eligible comparison. S11's 60 allocated participants, 28 and 26 completers by arm, and 60 participants in the flowchart are records for other endpoints. S11	An unspecified analysis in the original source is not filled in as ITT or as an HbA1c analysis of all participants.	Direct randomized/completed/analysis n, ITT/PP and reasons for/handling of missing data	For each eligible result, compare the recruitment→allocation→completion→analysis flow and handling of missing data.
14	Unverified	Full text not readStored summary read	N14 · Design and allocationAre allocation, concealment and baseline balance known for the direct HbA1c result?Required (selected sole-added-biotin/HbA1c comparison)	The retained evidence reports adjacent designs, including randomized blinded studies in S02/S04 and a single-center computer-randomized open-label trial in S11. The link between a directly eligible HbA1c result and its design is unverified. S02 S04 S11	The reference to trial_families.json in evidence does not mean that the file was read in this review.	Actual eligible comparison design, randomized/nonrandomized allocation, concealment and baseline balance	Compare the protocol/allocation documents and baseline tables for the direct comparison.
15	Unverified	Full text not readStored summary read	N15 · Adherence and rescue treatmentAre actual adherence, diabetes medication changes, diet and exercise known?Required (selected sole-added-biotin/HbA1c comparison)	adherence, background_diabetes_medication, medication_change_rescue and diet_exercise have null values/not_verified for the directly eligible comparison. These are separate verification items from the nominal common metformin exposure in S11. S11	Concurrent changes/handling needed for an actual incremental-effect analysis were not filled in solely from a nominal regimen in an adjacent study.	adherence, background meds, rescue/change, diet/exercise and handling in the analysis	Link adherence, rescue-treatment and arm-specific change records for the eligible original result.
16	Partly verified	Full text not readStored summary read	N16 · Planning and selective reportingWere the planned HbA1c outcome, analysis and time points compared with what was reported?Required (selected sole-added-biotin/HbA1c comparison)	S13/S14 are registry shells, and S15 is an indexed excerpt/shell. The historical limitation that some registry record texts, histories, protocols and SAPs could not be adequately obtained is explicitly stated in KO. S13 S14 S15	Having a registration number/link does not mean that the prespecified HbA1c plan has been verified. External lookups in this review: 0.	Registry record text, history, protocol, SAP, actual results and reasons for changes	Compare the eligible candidate's registry history and original plan with the actual results.
17	Met	Full text not readStored summary read	N17 · Adjacent sole-biotin treatmentWere Maebashi's fasting-glucose findings transferred to HbA1c?Required (selected sole-added-biotin/HbA1c comparison)	F01/S01 concern fasting-glucose and circulating-biotin results, not between-group HbA1c results. The original KO did not recast the observed low levels as a trial treating confirmed deficiency. S01	The publisher_full_pdf level reported at the time does not mean an external PDF was read now. Specific numbers are referenced separately in numeric_evidence and were not read this time.	Maebashi’s actual population, ingredient, comparator, time point and endpoint, and whether a between-group HbA1c result exists	Verify S01’s actual HbA1c results/plans during an authorized update.
18	Met	Full text not readStored summary read	N18 · Baseline valuesIs Báez-Saldaña’s baseline glycated hemoglobin a follow-up effect?Required (selected sole-added-biotin/HbA1c comparison)	F02/S02/S03 contain baseline glycated hemoglobin and enzyme/other metabolic-marker data; an eligible between-group HbA1c change/endpoint effect was not verified. The evidence field reports a randomized, blinded 28-day protocol after a cross-sectional phase. S02 S03	Verifying a study’s existence and baseline values does not establish a direct follow-up effect.	Baseline and follow-up HbA1c; the 28-day comparison; table/analysis definitions	Verify the HbA1c follow-up contrast, denominator and time point in the original results tables.
19	Partly verified	Full text not readStored summary read	N19 · Dose correctionWere the location-specific values in the µmol/day erratum preserved?Required (selected sole-added-biotin/HbA1c comparison)	KO preserves the correction of 6.14 µmol/day to 61.4 µmol/day at several daily-dose locations and the 20.5 µmol/day notation at another specified location. S02/S03 belong to one study-and-erratum family. S02 S03	The retained erratum summary was read, but the original bytes and each detailed location in the external erratum were not read this time. New conversions/corrections: 0.	Relevant locations in the original text and erratum; the 6.14/61.4/20.5 µmol notations; the relationship between versions	Verify the original bytes, locations and versions of the original text and erratum, and update each exposure record.
20	Met	Full text not readStored summary read	N20 · Other endpointsAre Revilla-Monsalve’s lipid/glucose results HbA1c?Required (selected sole-added-biotin/HbA1c comparison)	F03/S04 is a 28-day randomized, blinded placebo comparison with lipid, fasting-glucose and insulin results. Between-group HbA1c results were not verified in the original material. S04	The current URL is a PubMed bibliographic record/abstract. Do not present historical access, including author text, as current reading of the full text at that URL.	S04’s actual lipid, FPG and insulin results, and eligible between-group HbA1c results	Verify S04’s original plan/results tables for the presence of eligible HbA1c.
21	Met	Full text not readStored summary read	N21 · Related add-on therapyWhat were the exposure and off-treatment periods in Devi/Ranjani?Required (selected sole-added-biotin/HbA1c comparison)	S11 allocated 60 participants, 30 per arm, with metformin 500 mg/day for 6 weeks as common treatment and biotin 5 mg 2 times daily for 4 weeks followed by 2 weeks off. The verified weekly endpoints are FPG/PPG. S11	This verifies preservation of the nominal exposure, not an actual eligible HbA1c result or a sustained long-term effect.	Biotin 5 mg 2 times daily for 4 weeks; 2 weeks off; metformin 500 mg/day for 6 weeks in both arms; actual endpoints	Verify administration, discontinuation and the presence of HbA1c at each time point in the original plan/results.
22	Conflicting information	Full text not readStored summary read	N22 · Conflicting informationWere the completer analyses by arm and the flowchart’s 60 participants both retained?Required (selected sole-added-biotin/HbA1c comparison)	S11’s results text/tables present completer analyses of control 28/biotin 26 participants, while the flowchart shows 60 completers. KO preserves both and explicitly states that Hb was not read as HbA1c. S11	Who was omitted or which denominator is correct was not resolved within the scope of the original retained material. These counts are not used as the eligible HbA1c analysis n either.	S11 results text/tables: control 28 and biotin 26 participants; flowchart: 60 completers; analysis definitions	Compare the original text, flowchart, corrections and analysis specifications to verify the reason for the denominator discrepancy.
23	Met	Full text not readStored summary read	N23 · Positive and nonsignificant findingsAre week 4 P=.001 and week 6 P=.087 the same result?Required (selected sole-added-biotin/HbA1c comparison)	In the same S11, the week 4 FPG endpoint comparison has nominal P=.001, and week 6 after discontinuation has P=.087. These are FPG results at different time points, not HbA1c. S11	Nonsignificance does not establish equivalence or an exactly null effect. No new CI/effect calculations were performed.	S11 FPG endpoint comparison: time point, whether biotin had been stopped, P, and whether the endpoint was HbA1c	Separately verify the prespecified plan, between-group estimates/intervals at each time point and the effect of discontinuation.
24	Met	Full text not readStored summary read	N24 · Positive combination-product findingWere 447 participants and P=.03 used as a biotin-only HbA1c result?Required (selected sole-added-biotin/HbA1c comparison)	Albarracin S05 reports 447 participants, a combination of chromium 600 µg+biotin 2 mg/day for 90 days versus placebo, and a between-group HbA1c-change P=.03. The positive finding is preserved and is not attributed to biotin alone. S05	The direct sole-biotin effect size, CI and clinical importance cannot be filled in from this combination result.	S05: chromium 600 µg+biotin 2 mg/day for 90 days versus placebo; 447 participants; between-group HbA1c P=.03	Separately verify an eligible HbA1c comparison in which only biotin differs against the same chromium background.
25	Partly verified	Full text not readStored summary read	N25 · Study families and denominatorsWere 348 participants and the active arm’s 226 participants counted as a different study/the total n?Required (selected sole-added-biotin/HbA1c comparison)	The related combination report’s 348 participants comprise active 226 and placebo 122 participants; 226 is not used as the total n. F04 conservatively groups possible overlap, and the S12 review is not added to its included studies. S05 S08 S12 S13	The number of unique independent trials/total participants is unconfirmed; new sums/back-calculations: 0.	S05/S08/S13 and review S12: study families; 348=active 226/placebo 122; overlap relationships	Compare recruitment, periods and participant links across the relevant reports and registries.
26	Partly verified	Full text not readStored summary read	N26 · Bibliographic candidateWere Singer/Geohas’s sample and results verified?Required (selected sole-added-biotin/HbA1c comparison)	S09 is primary_index_only for a chromium-biotin combination pilot report. F05’s S14 registry linkage is provisional, and the exact study-to-report link is unconfirmed. S09 S14	The historical scope did not yield result extraction beyond the retained title/index; new access to the original text this time: 0.	S09 original text and results tables; actual study linkage to registry S14; sole/combination composition	Compare the S09 original text with the S14 history and actual recruitment/results.
27	Met	Full text not readStored summary read	N27 · Other populationsWere type 1 HbA1c candidates transferred to T2D?Required (selected sole-added-biotin/HbA1c comparison)	F06/S10 is a biotin add-on-to-insulin study in type 1 diabetes and is not directly attributed to the adult T2D question. The historical PMC full access challenge/partial abstract level is preserved separately. S10	The PMC full text was not read this time, and results in the other population were not deleted.	S10’s actual type1 population, common insulin treatment and extraction level	Verify direct T2D results separately and retain type1 data for a different question.
28	Partly verified	Full text not readStored summary read	N28 · Registered sole-biotin armWas GUTERRING excluded solely because its title mentions a combination?Required (selected sole-added-biotin/HbA1c comparison)	F08/S15 is a biotin-only arm candidate in an officially indexed pilot open-label randomized 4-arm design. KO records that it was not excluded solely because of the combination wording in the title, but direct T2D HbA1c results remain unverified. S15	An indexed excerpt/shell does not constitute obtaining the complete registry plan/results.	NCT05832190’s actual 4 arms, biotin-only arm, population/follow-up HbA1c results and plan	Verify the registry body/history, population, actual biotin-only arm results and HbA1c time points.
29	Partly verified	Full text not readStored summary read	N29 · Review and independent replicationIs a review counted as an original trial or independent verification?Required (selected sole-added-biotin/HbA1c comparison)	S12 is a 2022 systematic review/meta-analysis serving as a literature map; the retained location is the HbA1c subsection/refs32–39. KO did not double-count the review, original papers, follow-up reports and registries. S01 S02 S04 S05 S08 S09 S11 S12 S13	What was actually read this time was the stored bibliography and linked KO. The external review’s original text, the original bytes of its inclusion tables and its numbers were not read.	The S12 review’s question, search cutoff, included studies/endpoints and links to original reports	Compare the review’s inclusion tables with the original reports’ results and the overlap/sole-ingredient boundaries.
30	Partly verified	Full text not readStored summary read	N30 · Older materialDo the discovery and access failure concerning Coggeshall constitute a negative result?Required (selected sole-added-biotin/HbA1c comparison)	F09/S16 is at the level of bibliographic discovery of a 1985 report. The population/eligible original between-group HbA1c results were not sufficiently verified, and the historical access_level is metadata_and_failed_full_text. S16	The failure at that time is not a failed access attempt this time. Do not count the candidate as a negative result.	S16’s actual original text, population, sole-biotin comparison, HbA1c follow-up and historical failure record	Verify the relevant original text, population and follow-up results during an authorized update.
31	Met	Full text not readStored summary read	N31 · Search scopeIs the lack of verified direct evidence expressed as 0 studies worldwide?Required (selected sole-added-biotin/HbA1c comparison)	The original KO/assessment limits its statement to not having verified directly eligible results within the documented search scope. S17 WHO ICTRP was internal error/access_failed at the time; current external lookups/searches: 0. S13 S14 S15 S16 S17	Do not retroactively treat the original verified_date/evidence reference date, 9/15, as the current full-text reading date.	The 2026-09-15 original review/search scope, ICTRP failure and scope of this reading of retained material	Verify search records, unpublished studies/registries and correction coverage in an authorized update as a separate event.
32	Partly verified	Full text not readStored summary read	N32 · Assay interferenceWas TSH/troponin interference generalized to interference with HbA1c itself?Required (selected sole-added-biotin/HbA1c comparison)	The retained NIH/FDA content concerns selected thyroid tests after a single 10 mg dose within 24 hours, selected TSH/NT-proBNP tests in 6 people receiving 10 mg/day for 1 week, and falsely low results in some troponin tests. It does not establish the same interference in every test/HbA1c method. S06 S07	Do not present the original official extract as actual access to the official full text this time. Do not provide personal dosing, stopping or testing schedules.	NIH/FDA’s specific assays, populations, exposures and time points, with separate verification of the HbA1c assay	Separately verify validation for each relevant HbA1c method and data on biotin exposure/blood-sampling time points.
33	Partly verified	Full text not readStored summary read	N33 · Related adverse eventsAre the frequencies of nausea, loose stools and gastric irritation in S11 known?Required (selected sole-added-biotin/HbA1c comparison)	KO preserves nausea, loose stools and gastric irritation from the trial with common metformin treatment and states that the safety-analysis denominator is unclear. The stored summary read this time retains a reference to numeric_evidence N12 instead of specific event counts. S11	The numeric file and original safety tables were not read this time. Do not elevate limited short-term experience involving another endpoint into long-term safety of sole-biotin add-on therapy.	People with AE/events by arm; collection; exposure/follow-up; safety-analysis denominators; discontinuation	Separately verify the original AE tables, collection methods and arm-specific denominators/discontinuations.
34	Unverified	Full text not readStored summary read	N34 · Long-term use and vulnerable groupsIs there safety evidence for long-term use, pregnancy/lactation, children, hepatic/renal disease and concurrent use?Supplementary; required for the corresponding extended claims about long-term or special-population safety	The original safety_detail explicitly states that long-term add-on use in T2D, pregnancy, lactation, children, hepatic/renal disease, concurrent use and eligible dose-specific AE/discontinuations are unverified. S06 S07 S11	Unverified information does not establish either safety or harm, and no personal dosing instructions are created.	Long-term AE and discontinuations by eligible dose; population-specific exposure/interactions and denominators	Separately verify long-term/population-specific harms and observation conditions for the same product and dose.
35	Unverified	Full text not readStored summary read	N35 · Independence and fundingIs the actual scope of funding, product provision and COI known?Required (selected sole-added-biotin/HbA1c comparison)	The funding fields of the 9 evidence items refer to trial_families.json for detailed verified and unverified information. The S11 location includes p106 COI, but the currently retained summary does not reproduce the specific disclosures. S01 S02 S04 S05 S08 S09 S10 S11 S15 S16	The existence of a referenced file or COI location does not mean its contents were read in this review. Do not infer the number of independent trials or lack of industry involvement.	Report-specific funding, product provision, author relationships, COI declarations and original verification locations	Verify original research funding/COI and product supply records by report.
36	Met	Full text not readStored summary read	N36 · Reading levelHave historical full-text access and current summary reading been separated?Required (selected sole-added-biotin/HbA1c comparison)	What was actually read in this review consists of the exact retained Korean content, bibliography and structure/metadata, with the retained summaries’ locations/values/SHA. publisher_full_pdf, author_text, official_extract, shell and failure are historical records; external materials/referenced historical ZIP files have not been read in this review. S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 S13 S14 S15 S16 S17	Each report’s historical access date is null because the source material contains no date; retain the review date 9/15 in a separate field. The existence of an external URL is not new acquisition.	Historical access_level/location by report; actual access dates; current local locations/values/SHA; external access unattempted	If new access is separately authorized, independently record the material/time/original bytes.
37	Met	Full text not readStored summary read	N37 · Original gate and scoreHave ?/null values and no_human_study=true been preserved unchanged?Required (selected sole-added-biotin/HbA1c comparison)	Preserve the original ?, null score, B/S, nulls on the subsequent 5 axes, no_human_study=true and human_study_exists=false unchanged. The assessment’s scope is direct eligible HbA1c results, and related_human_studies_exist=true.	Blue in this table indicates verification of the stated preservation/boundary criteria; it does not establish a direct effect, constitute official methodological certification or represent a new verdict.	Original ?/null score; B/S; nulls on the subsequent 5 axes; bounded human scope; related studies true	If direct evidence is added, consider a separate update that preserves the original values/reasons for change.
38	Met	Full text not readStored summary read	N38 · Technical and deployment metadataHave server_deployed and actual deployment in this work been distinguished?Required (selected sole-added-biotin/HbA1c comparison)	Preserve the original server_deployed=true, server_write_performed=false, deployed_at 2026-09-15 and initial snapshot scope. This work is a local table conversion, with 0 public site deployments.	Do not certify the current actual publication status solely from the original metadata.	Original server_deployed/server_write_performed/first_published_scope; current local preparation	If actual publication is separately authorized, verify the production URL/display/links and record the event.
39	Not applicable	Full text not readStored summary read	N39 · Boundaries for extensionsDoes the HbA1c table also answer questions about clinical events and improvements in quality of life?Supplementary; required for extended claims about clinical events, duration and dose	The selected question concerns between-group numerical HbA1c results. The original assessment uses an S surrogate and does not upgrade it to an H clinical event/P functional endpoint.	The criterion is not applicable because event studies are not required to complete this numerical table; this does not substitute for verification or nonverification of clinical-event benefits.	Boundary between the selected HbA1c question and separate questions about complications, quality of life, mortality, duration/dose	Review direct results and criteria separately for questions about events/long-term outcomes/dose.
40	Met	Full text not readStored summary read	N40 · Updating and trackingWhat changes when new direct results, full texts or corrections are acquired?Required (selected sole-added-biotin/HbA1c comparison)	The original revision_triggers are new direct HbA1c results, full texts/registrations/SAPs, corrections/retractions, numerical/classification errors and new safety materials. Maintain the same ID/URL and the policy of retaining old/new/reason/source/date.	No new search, calculation, update to the original verdict or public release was performed in this work.	Original identity/dates; original values before/after; corrections/retractions; criterion versions; update links	Register separately authorized full texts, direct HbA1c results and corrections with their exact locations/values/hashes, then review the linked items again.

No items match your search or filter.

40 itemsWhat the statuses mean

Assessment scope

Stored-material review date: 2026-10-05
Original evidence date: 2026-09-15
Scope actually checked: Stored Korean and English manuscripts and case-specific criteria and application records. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of an up-to-date clinical literature search.
Population: Adults with type 2 diabetes; confirmed deficiency correction, type 1, gestational and drug-induced diabetes, prediabetes and healthy populations are separate; unreported biotin status is not presumed normal
Ingredient, formulation and route: Biotin (biotin, vitamin B7), sole added active ingredient · The question is bounded to an oral product with a sole active ingredient; eligible product formulation, excipients, batch and purity are unverified · Oral; topical and injectable routes excluded
Dose: Unverified — dose, frequency, dietary intake and total concurrent supplemental intake for an eligible regimen
Comparator: Placebo, no biotin supplement or usual care under the same background conditions; the actual eligible comparator is unverified. Maintaining common diabetes treatment is a separate condition
Measured outcome: Priority is given to the between-group HbA1c change difference (%p) at a prespecified follow-up; an appropriately adjusted between-group endpoint contrast is separate. FPG, PPG, insulin, HOMA-IR and fructosamine are not substitutes
Duration: Unverified — eligible treatment duration and prespecified HbA1c follow-up
Questions outside this scope: Common metformin is allowed; mixtures with a concurrent change in chromium, confirmed deficiency correction, type 1/gestational/healthy populations, FPG/PPG/Hb and clinical events/assay bias are separate. The candidate GUTERRING biotin-only arm is retained. /subclaims=[]

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Maebashi et al. 1993. Therapeutic Evaluation of the Effect of Biotin on Hyperglycemia in Patients with Non-Insulin Dependent Diabetes Mellitus

Source

Material type: Reports on biotin alone and other endpoints
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: S01 fasting-glucose/blood-biotin data; direct between-group HbA1c result unverified
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: publisher_full_pdf. Historically recorded location: J Clin Biochem Nutr 14:211–218; Methods pp212–213; results p214; whole-paper endpoint inspection. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
Publisher PDF link	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: publisher_full_pdf. Historically recorded location: J Clin Biochem Nutr 14:211–218; Methods pp212–213; results p214; whole-paper endpoint inspection. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S02 · Báez-Saldaña et al. 2004. Effects of biotin on carboxylases and markers for glucose and lipid homeostasis

Source

Material type: Original report on biotin alone
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: S02 baseline glycated hemoglobin and enzyme/metabolic markers; follow-up between-group HbA1c result unverified
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: author_uploaded_full_text. Historically recorded location: Am J Clin Nutr 79:238–243; p239 procedures; Table2 p241; discussion p242; baseline characteristics. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
Author-shared full-text page	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: author_uploaded_full_text. Historically recorded location: Am J Clin Nutr 79:238–243; p239 procedures; Table2 p241; discussion p242; baseline characteristics. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S03 · Báez-Saldaña et al. 2007. Erratum to 2004 biotin study

Source

Material type: S02 dose erratum
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Preserve location-specific 6.14→61.4 µmol/day and 20.5 µmol/day at other specified locations; new conversions: 0
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: author_uploaded_correction_text. Historically recorded location: Am J Clin Nutr 85:570; correction paragraph. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
Author-shared correction page	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: author_uploaded_correction_text. Historically recorded location: Am J Clin Nutr 85:570; correction paragraph. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S04 · Revilla-Monsalve et al. 2006. Biotin supplementation reduces plasma triacylglycerol and VLDL

Source

Material type: Reports on biotin alone and other endpoints
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Lipids, FPG and insulin; eligible between-group HbA1c result unverified
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: primary_abstract_and_author_text. Historically recorded location: Biomed Pharmacother 60:182–185; abstract; Methods subjects/treatment and outcome table. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
PubMed bibliographic record and abstract	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. S04’s historical access to the author’s text does not mean current full-text reading at this PubMed URL. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: primary_abstract_and_author_text. Historically recorded location: Biomed Pharmacother 60:182–185; abstract; Methods subjects/treatment and outcome table. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S05 · Albarracin et al. 2008. Chromium picolinate and biotin combination improves glucose metabolism

Source

Material type: Chromium–biotin combination HbA1c report
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: 447 participants, 90 days; chromium 600µg+biotin 2mg/P=.03; not attributable to biotin alone
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: pubmed_primary_abstract. Historically recorded location: Diabetes Metab Res Rev 24:41–51; abstract Methods/Results. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
PubMed bibliographic record and abstract	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: pubmed_primary_abstract. Historically recorded location: Diabetes Metab Res Rev 24:41–51; abstract Methods/Results. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S06 · NIH Office of Dietary Supplements: Biotin—Health Professional Fact Sheet

Source

Material type: Official NIH safety materials
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Biotin interference under specific assay and exposure conditions; does not demonstrate interference with HbA1c itself or all tests
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: inherited_official_extract. Historically recorded location: Table1; Health Risks from Excessive Biotin; Interactions with Laboratory Tests, refs9/38. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
Official NIH ODS web document	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: inherited_official_extract. Historically recorded location: Table1; Health Risks from Excessive Biotin; Interactions with Laboratory Tests, refs9/38. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S07 · FDA: Biotin Interference with Troponin Lab Tests—Assays Subject to Biotin Interference

Source

Material type: FDA troponin assay safety materials
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Falsely low results in some troponin assays; not direct evidence of actual HbA1c efficacy/risk rates
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: inherited_official_extract. Historically recorded location: Opening safety statement and paragraphs on residual assay interference. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
Official FDA web document	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: inherited_official_extract. Historically recorded location: Opening safety statement and paragraphs on residual assay interference. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S08 · Albarracin et al. 2007. Chromium and biotin: coronary risk factors in type 2 diabetes

Source

Material type: Related follow-up report on the combination
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: 348 participants, active 226/placebo 122; possible shared cohorts conservatively grouped/independent summations: 0
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: primary_abstract_mirror. Historically recorded location: J Cardiometab Syndr 2:91–97; abstract N=348, active226/placebo122. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
PubMed bibliographic record and abstract	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: primary_abstract_mirror. Historically recorded location: J Cardiometab Syndr 2:91–97; abstract N=348, active226/placebo122. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S09 · Singer and Geohas 2006. Chromium picolinate and biotin supplementation in poorly controlled type 2 diabetes

Source

Material type: Bibliographic candidate for a combination pilot
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Original outcome extraction not acquired; S14 linkage provisional; not direct data on HbA1c from biotin alone
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: primary_index_only. Historically recorded location: Title and bibliographic record; full outcome extraction not obtained. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
PubMed bibliographic record and abstract	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: primary_index_only. Historically recorded location: Title and bibliographic record; full outcome extraction not obtained. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S10 · Hemmati et al. 2013. Survey of biotin, glycemic control and plasma lipids in type 1 diabetes

Source

Material type: Report in a different population: type 1 diabetes
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Type 1 insulin add-on data; excluded from the direct T2D question/historical partial PMC access
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: primary_abstract_index_partial. Historically recorded location: Title/abstract population; full PMC access challenge. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
PMC full-text page	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: primary_abstract_index_partial. Historically recorded location: Title/abstract population; full PMC access challenge. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S11 · Devi and Ranjani 2016. Biotin added to metformin versus metformin alone in newly diagnosed type 2 diabetes

Source

Material type: Sole added active ingredient: FPG/PPG report
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Common metformin allowed; HbA1c unverified; completers 28/26 versus flowchart 60; FPG P values at 4/6 weeks preserved
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: publisher_full_pdf. Historically recorded location: IOSR-JDMS 15(7)IX:100–106; p101 methods/flowchart; p102 completers/Table4; p104 Tables6–7; p105 Tables8–9; p106 COI. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
Publisher PDF link	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: publisher_full_pdf. Historically recorded location: IOSR-JDMS 15(7)IX:100–106; p101 methods/flowchart; p102 completers/Table4; p104 Tables6–7; p105 Tables8–9; p106 COI. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S12 · Zhang et al. 2022. Biotin interventions in type 2 diabetes: systematic review and meta-analysis

Source

Material type: Systematic review/meta-analysis
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Included studies, combinations/sole ingredients and endpoints must be distinguished; duplicate summations as independent trials: 0
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: publisher_full_text. Historically recorded location: Methods/search cutoff; HbA1c subsection; references32–39. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
Publisher’s review full-text page	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: publisher_full_text. Historically recorded location: Methods/search cutoff; HbA1c subsection; references32–39. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S13 · ClinicalTrials.gov NCT00289354

Source

Material type: NCT00289354 registry record
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Registry URL/shell for the combination family; not upgraded to verification of the body text or plan
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: registry_shell_only. Historically recorded location: Record URL verified, rendered body not available. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
ClinicalTrials.gov registry page	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: registry_shell_only. Historically recorded location: Record URL verified, rendered body not available. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S14 · ClinicalTrials.gov NCT00308451

Source

Material type: NCT00308451 registry record
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Shell only; exact report linkage unconfirmed; not counted as a new independent study
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: registry_shell_only. Historically recorded location: Record URL accessed; exact study-to-report link not established. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
ClinicalTrials.gov registry page	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: registry_shell_only. Historically recorded location: Record URL accessed; exact study-to-report link not established. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S15 · ClinicalTrials.gov NCT05832190: GUTERRING

Source

Material type: GUTERRING registry candidate
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: 4-arm/biotin-only-arm candidate retained; eligible T2D HbA1c results/body text unverified
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: registry_search_excerpt_and_shell. Historically recorded location: Official indexed title/design excerpt; direct body unavailable. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
ClinicalTrials.gov registry page	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: registry_search_excerpt_and_shell. Historically recorded location: Official indexed title/design excerpt; direct body unavailable. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S16 · Coggeshall et al. 1985. Biotin Status and Plasma Glucose in Diabetics

Source

Material type: Older bibliographic record; full text not acquired
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: 1985 full text/eligible population/between-group HbA1c details unverified; the failure at the time was not a negative result
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: metadata_and_failed_full_text. Historically recorded location: Ann NY Acad Sci 447:389–392; article identified, outcome detail inaccessible. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
Publisher’s article page	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: metadata_and_failed_full_text. Historically recorded location: Ann NY Acad Sci 447:389–392; article identified, outcome detail inaccessible. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

S17 · WHO ICTRP portal search for biotin

Source

Material type: WHO ICTRP search record
Materials actually read: The relevant Korean and English summaries and bibliographic records in the retained manuscript were read. The linked external original sources have not been read in this review.
Findings recorded in the stored summary: Historical internal error/access_failed; not an outcome or evidence of 0 studies worldwide
Record level: Information recorded in the retained manuscript. It is not the result of a new comparison against external original sources in this review.
Study overlap and independent replication: 17 bibliographic records ≠ 17 independent trials. Distinguish studies/corrections, possible duplicates/registrations, reviews/official safety sources/search roles; new summations of trials/participants: 0

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Retained archived summary: bibliography, linked summary/historical access	Retained locally	Acquired	Summary read	Exact retained-summary location/value/SHA, not the original bytes of the clinical full text. What was read in this review consists of the retained report summaries and bibliographic records. This does not mean that the original bytes of external clinical full texts were acquired. Historical access level recorded for the report: access_failed. Historically recorded location: Search endpoint attempted, returned internal error. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.
WHO ICTRP search page	Unverified (0 external lookups in this review)	Access not attempted	Not read	Indicates the physical material type of the link target. Distinguishes historical access from access not attempted and materials not read in this review. No attempt was made to access this external material or read its full text in this review. What was read consists of the retained report summaries. Historical access level recorded for the report: access_failed. Historically recorded location: Search endpoint attempted, returned internal error. Historical report-level access is not inherited as the material’s current reading status. The actual historical access date is unverified, and the retained manuscript’s review date 2026-09-15 is not an access date for the original source.

Report counts versus independent study counts

These are report linkages from the original material. The 17 citations, 9 retained evidence items and 10 family links are different structural counts, not the number of independent eligible direct clinical trials. S01: F01: excluded from direct efficacy scoring / S02, S03: F02: excluded from direct efficacy scoring / S04: F03: excluded from direct efficacy scoring / S05, S08, S13: F04: excluded from direct efficacy scoring / S09, S14: F05: excluded from direct efficacy scoring / S10: F06: excluded from direct efficacy scoring / S11: F07: excluded from direct efficacy scoring / S15: F08: excluded from direct efficacy scoring / S16: F09: excluded from direct efficacy scoring / S06, S07, S12, S17: official safety sources, review literature map and historical search failure; not counted as independent direct HbA1c trials. Original reports, corrections, follow-up reports, registrations and reviews are not added as independent replications. Possible shared cohorts and provisional registry links are retained; unique trial and total participant counts remain unverified.

Review criteria

Version NGM-v3105-SOLE-BIOTIN-T2D-HBA1C-1.0 · Criteria record date 2026-10-05. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which biotin, population and HbA1c comparison does the question concern?

Required materials and conditions: Adults with T2D · Oral biotin as the sole addition · Comparator with identical background conditions · Between-group HbA1c result at a prespecified time point
Conditions for verification: Link the current original effect wording to the actual inclusion/exclusion boundaries and original pointers.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Type 1/gestational/healthy populations, confirmed deficiency correction, topical/injectable routes and concurrent changes in chromium are separate.
Why this condition is needed: Needed to avoid combining the ingredient as a whole or all glycemic markers into a single result.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed

N02 · Does common metformin treatment exclude a comparison of a sole added ingredient?

Required materials and conditions: Background treatment in both arms, added ingredients, arm-specific changes/rescue treatment and the actual effect of interest
Conditions for verification: Distinguish the difference in added ingredients from common treatment and link this distinction to endpoint eligibility.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: A comparison of biotin as the sole addition is not excluded merely because it is described as concomitant treatment.
Why this condition is needed: Common treatment must be distinguished from active ingredients that change concurrently.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application

N03 · Are the chemical form, origin and manufacturer of the directly eligible product known?

Required materials and conditions: Exact chemical form, origin, manufacturer and documentation verifying the active ingredient
Conditions for verification: Separate verified values for the directly eligible product from null values and reasons for nonverification.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Naming biotin in the question does not verify the chemical form of the actual preparation.
Why this condition is needed: Needed to avoid filling in the identity of an eligible HbA1c regimen with a product from another study.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed

N04 · Are tablet/capsule form, excipients, brand, batch and purity verified?

Required materials and conditions: Formulation, excipients, brand, batch/purity and other added active ingredients
Conditions for verification: Identify the actual locations verifying the eligible formulation and composition/quality, or mark them as unverified.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Specifications of a combination product are not transferred as verification of a sole-active product.
Why this condition is needed: Needed to avoid claiming identical composition and quality based solely on a product name.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed

N05 · What are the eligible biotin dose, frequency and total exposure?

Required materials and conditions: Eligible dose/frequency, dietary biotin, concurrent supplements and actual exposure
Conditions for verification: Explain what is verified and what is missing about the actual dose and total exposure linked to the selected result.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not arbitrarily convert values expressed in mg, µmol and µg at different source locations into mass equivalents.
Why this condition is needed: Needed to avoid using quantities from adjacent FPG studies or safety cases as an HbA1c regimen.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed

N06 · Have the treatment duration and HbA1c follow-up time been specified?

Required materials and conditions: Actual treatment duration, prespecified follow-up time and separate post-discontinuation time point
Conditions for verification: Link the eligible treatment duration and prespecified HbA1c follow-up to the original plan/results.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not arbitrarily adopt a common minimum treatment duration.
Why this condition is needed: Needed to avoid transferring FPG at 4/6 weeks or a combination product at 90 days into the same HbA1c time point.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed

N07 · Are confirmed T2D diagnosis, baseline HbA1c and disease duration verified?

Required materials and conditions: Diagnostic criteria, age, baseline HbA1c, disease duration and population composition
Conditions for verification: Link the actual eligible population/baseline composition to the unverified items.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Type 1, gestational and drug-induced diabetes, prediabetes and healthy populations are retained as separate questions.
Why this condition is needed: Needed to avoid filling in the actual baseline status of the eligible sample from the population label alone.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed

N08 · Have observations of low biotin been recast as confirmed deficiency correction?

Required materials and conditions: baseline_biotin, deficiency_assay, deficiency definition and eligible status
Conditions for verification: Separate the status verified by the original source from the level of diagnosis that remains unverified.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Unreported status is not presumed normal, and a trial is not described as treating deficiency solely because low levels were observed.
Why this condition is needed: Needed to distinguish blood-level observations, unreported status and treatment of confirmed deficiency.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed

N09 · Were between-group HbA1c changes distinguished from other glycemic outcomes?

Required materials and conditions: Prespecified between-group HbA1c change difference in %p, adjusted endpoint contrast and measurement/analysis definitions
Conditions for verification: Attribute observations to the selected endpoint, unit, time point and analysis.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not automatically equate an adjusted endpoint contrast with a change difference.
Why this condition is needed: Needed to avoid interpreting FPG/PPG, insulin, HOMA-IR, fructosamine or Hb as HbA1c.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

N10 · Are the HbA1c assay method and red-cell-related factors verified?

Required materials and conditions: HbA1c assay, interference, anemia/RBC lifespan, transfusion/Hb variants and renal function
Conditions for verification: Explain the actual assay method and arm-specific measurement conditions for the selected HbA1c outcome, and what remains unverified.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Biotin interference in specific immunoassays is not generalized to all HbA1c methods.
Why this condition is needed: Needed to distinguish changes in measured values from assay/red-cell conditions.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; design considerations in M19 §19.2.2–19.2.4; detailed confounding records are internally designed

N11 · Is there an eligible between-group HbA1c estimate for biotin alone?

Required materials and conditions: Directly eligible between-group HbA1c effect, follow-up time point, denominator and original result location
Conditions for verification: Link the direct estimate or an explicit gap within the currently verified scope.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Failure to verify a direct result is not described as an effect of 0 or an absence of human studies worldwide.
Why this condition is needed: Needed to distinguish the existence of related human studies from obtaining a direct result for this question.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.5, §4.6.3; limits on the current material conversion follow the user's scope and internal design; M08 §8.2.2, M15 §15.3.1; internal application

N12 · Can the effect magnitude be interpreted using CI, P and MCID?

Required materials and conditions: Direct effect, confidence interval, variance, denominator and justified importance threshold
Conditions for verification: Distinguish reported direct intervals/importance thresholds from the reasons interpretation is not possible.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not arbitrarily set a minimum sample size, number of trials or numerical HbA1c importance threshold.
Why this condition is needed: Needed to avoid equating a P value with clinical importance or precision.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M15 §15.3.1–15.3.3; internal application

N13 · Are the allocation, completion, analysis and ITT/PP denominators linked?

Required materials and conditions: Direct randomized/completed/analysis n, ITT/PP and reasons for/handling of missing data
Conditions for verification: Show the actual denominator and handling for the relevant HbA1c outcome, or mark them as unverified.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not sum n across different reports or arbitrarily reconcile flowchart conflicts.
Why this condition is needed: Needed to avoid using allocation or completion counts from another endpoint as HbA1c denominators.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

N14 · Are allocation, concealment and baseline balance known for the direct HbA1c result?

Required materials and conditions: Actual eligible comparison design, randomized/nonrandomized allocation, concealment and baseline balance
Conditions for verification: Distinguish the verified design information for the selected result from the scope that remains unverified.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: An unverified design is not labeled as crossover/cluster inapplicability or an automatic failure on bias.
Why this condition is needed: Needed to avoid transferring a description of an adjacent randomized study as verification of the design for the selected HbA1c result.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M08 §8.1–8.2.3; internal application

N15 · Are actual adherence, diabetes medication changes, diet and exercise known?

Required materials and conditions: adherence, background meds, rescue/change, diet/exercise and handling in the analysis
Conditions for verification: Explain arm-specific concurrent changes and adherence in the eligible comparison, and the gaps.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Verify the actual effect of interest and the handling methods rather than requiring all changes to be identical.
Why this condition is needed: Needed to separate concurrent changes from biotin's contribution.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application

N16 · Were the planned HbA1c outcome, analysis and time points compared with what was reported?

Required materials and conditions: Registry record text, history, protocol, SAP, actual results and reasons for changes
Conditions for verification: Identify the locations showing what was actually compared and the plans/time points not compared.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Failure to obtain material is not recast as confirmed nonregistration or selective reporting.
Why this condition is needed: Needed to distinguish a registry shell from verification of the original plan.
Referenced methods: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current material conversion follow the user's scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

N17 · Were Maebashi's fasting-glucose findings transferred to HbA1c?

Required materials and conditions: Maebashi’s actual population, ingredient, comparator, time point and endpoint, and whether a between-group HbA1c result exists
Conditions for verification: Link the originally retained S01 results to the reason for exclusion from direct evidence.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not reclassify observations of low circulating biotin or the long-term combination arm as a sole-biotin comparison treating confirmed deficiency.
Why this condition is needed: Needed to distinguish the existence of biotin-only studies from an eligible HbA1c result.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

N18 · Is Báez-Saldaña’s baseline glycated hemoglobin a follow-up effect?

Required materials and conditions: Baseline and follow-up HbA1c; the 28-day comparison; table/analysis definitions
Conditions for verification: Distinguish S02’s baseline/other results from the unverified eligible effect.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not recast enzyme or metabolic markers as between-group HbA1c follow-up results.
Why this condition is needed: Needed to avoid misreading baseline characteristics as an estimate of between-group change.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

N19 · Were the location-specific values in the µmol/day erratum preserved?

Required materials and conditions: Relevant locations in the original text and erratum; the 6.14/61.4/20.5 µmol notations; the relationship between versions
Conditions for verification: Link the location-specific correction notations and remaining identity/interpretation limitations to the original text.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not turn unclear locations or units into arbitrary mg conversions or personal prescriptions.
Why this condition is needed: Needed to avoid creating a new dose by ignoring the erratum or standardizing the values to a single value.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

N20 · Are Revilla-Monsalve’s lipid/glucose results HbA1c?

Required materials and conditions: S04’s actual lipid, FPG and insulin results, and eligible between-group HbA1c results
Conditions for verification: Link the other endpoints in the original record to the reason for exclusion from direct HbA1c evidence.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not establish an endpoint match solely from the 28-day randomized placebo design.
Why this condition is needed: Needed to avoid substituting changes in other metabolic markers for the selected endpoint.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

N21 · What were the exposure and off-treatment periods in Devi/Ranjani?

Required materials and conditions: Biotin 5 mg 2 times daily for 4 weeks; 2 weeks off; metformin 500 mg/day for 6 weeks in both arms; actual endpoints
Conditions for verification: Link the retained exposure, common treatment and off-treatment period to the verified endpoints.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not recast 4 weeks of use as 6 weeks of continuous exposure or HbA1c follow-up.
Why this condition is needed: Needed to preserve this candidate added-ingredient comparison without confusing duration and endpoints.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; details on dose, persistence and effect modification are internally designed

N22 · Were the completer analyses by arm and the flowchart’s 60 participants both retained?

Required materials and conditions: S11 results text/tables: control 28 and biotin 26 participants; flowchart: 60 completers; analysis definitions
Conditions for verification: Preserve conflicting denominators within the same report and the limits on attributing results/endpoints.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not read blood-test Hb as HbA1c. Recalculations of the original numbers/changes to the flowchart: 0.
Why this condition is needed: Needed to avoid arbitrarily reconciling the conflicting completion/analysis denominators into the selected HbA1c sample.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

N23 · Are week 4 P=.001 and week 6 P=.087 the same result?

Required materials and conditions: S11 FPG endpoint comparison: time point, whether biotin had been stopped, P, and whether the endpoint was HbA1c
Conditions for verification: Retain the differences in results and exposure at the two time points together with the limits on direct attribution.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not transfer FPG results at different time points to an HbA1c effect or turn nonsignificance into an effect of 0.
Why this condition is needed: Needed to avoid selecting only the positive time point or treating nonsignificance as equivalence.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M15 §15.3.1–15.3.3; internal application; M03 §3.2.1–3.2.4; details on dose, persistence and effect modification are internally designed

N24 · Were 447 participants and P=.03 used as a biotin-only HbA1c result?

Required materials and conditions: S05: chromium 600 µg+biotin 2 mg/day for 90 days versus placebo; 447 participants; between-group HbA1c P=.03
Conditions for verification: Link the combination-product results to the reason for exclusion from sole-biotin evidence.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: The same background diabetes treatment does not isolate the incremental effects of chromium/biotin individually.
Why this condition is needed: The positive HbA1c result must be preserved while limiting attribution because another ingredient also changed.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

N25 · Were 348 participants and the active arm’s 226 participants counted as a different study/the total n?

Required materials and conditions: S05/S08/S13 and review S12: study families; 348=active 226/placebo 122; overlap relationships
Conditions for verification: Distinguish verified families/unconfirmed overlaps and report-specific denominators.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not convert a possibly shared cohort into either confirmed independence or confirmed complete identity.
Why this condition is needed: Needed to avoid double-counting original reports, follow-up reports, registries and reviews as replication trials or participants.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

N26 · Were Singer/Geohas’s sample and results verified?

Required materials and conditions: S09 original text and results tables; actual study linkage to registry S14; sole/combination composition
Conditions for verification: Identify the verified title/index and the unverified original results/registry linkage.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not establish a confirmed shared family or participant count when the registry-number linkage is provisional.
Why this condition is needed: Needed to distinguish bibliographic discovery from verification of eligible results.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

N27 · Were type 1 HbA1c candidates transferred to T2D?

Required materials and conditions: S10’s actual type1 population, common insulin treatment and extraction level
Conditions for verification: Link S10’s actual population mismatch to the historical access limitations.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not delete data from other populations or use them as evidence that no human studies exist.
Why this condition is needed: Needed to avoid counting human studies in a population different from the question’s population as direct results.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

N28 · Was GUTERRING excluded solely because its title mentions a combination?

Required materials and conditions: NCT05832190’s actual 4 arms, biotin-only arm, population/follow-up HbA1c results and plan
Conditions for verification: Indicate separately the retention of the registry candidate and the lack of verified direct results.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not claim that an eligible T2D HbA1c result has been verified solely because a biotin-only arm exists.
Why this condition is needed: Needed to avoid omitting a potential biotin-only arm candidate solely on the basis of the title.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

N29 · Is a review counted as an original trial or independent verification?

Required materials and conditions: The S12 review’s question, search cutoff, included studies/endpoints and links to original reports
Conditions for verification: Distinguish the review’s role and the family/endpoint differences among its included original studies.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not claim to have read the entire review/numeric files this time.
Why this condition is needed: Needed to avoid counting mixtures of endpoints/ingredients and repeated citations as independent results.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

N30 · Do the discovery and access failure concerning Coggeshall constitute a negative result?

Required materials and conditions: S16’s actual original text, population, sole-biotin comparison, HbA1c follow-up and historical failure record
Conditions for verification: Separate the retained discovery/historical failure from the current unread status and the lack of verified eligible evidence.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not use metadata_and_failed_full_text to represent a current failed-access action or worldwide study absence.
Why this condition is needed: Needed to distinguish a candidate whose original text was not obtained from no effect.
Referenced methods: M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

N31 · Is the lack of verified direct evidence expressed as 0 studies worldwide?

Required materials and conditions: The 2026-09-15 original review/search scope, ICTRP failure and scope of this reading of retained material
Conditions for verification: Link every expression of absence or lack of verification to its actual scope and date.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: The 0 searches this time do not mean 0 studies. Historical selection_log/ZIP references do not constitute current acquisition.
Why this condition is needed: Needed to distinguish a bounded gate from complete absence of literature.
Referenced methods: M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

N32 · Was TSH/troponin interference generalized to interference with HbA1c itself?

Required materials and conditions: NIH/FDA’s specific assays, populations, exposures and time points, with separate verification of the HbA1c assay
Conditions for verification: Separate the assay/exposure scope of the retained safety material from the lack of verification for the selected HbA1c endpoint.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Statements concerning specific TSH/NT-proBNP/troponin tests do not directly establish interference with an HbA1c assay.
Why this condition is needed: Needed to avoid turning biotin interference into actual glycemic improvement or a risk for every test.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; detailed distinctions are internally designed; M19 §19.2 design-specific harm questions; temporal-relationship details are internally designed; Chamgap’s own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied

N33 · Are the frequencies of nausea, loose stools and gastric irritation in S11 known?

Required materials and conditions: People with AE/events by arm; collection; exposure/follow-up; safety-analysis denominators; discontinuation
Conditions for verification: Link the retained symptoms to gaps in safety denominators/directly eligible exposure.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not calculate event rates or NNH from unclear safety denominators, or treat unreported data as 0.
Why this condition is needed: Needed to distinguish the presence of symptoms from incidence rates or a guarantee of long-term safety.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; detailed distinctions are internally designed; M19 §19.2.2–19.2.4 design considerations; detailed confounding records are internally designed; M19 §19.1.2–19.2.4, M04 §4.6.3; internal application; Chamgap’s own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied

N34 · Is there safety evidence for long-term use, pregnancy/lactation, children, hepatic/renal disease and concurrent use?

Required materials and conditions: Long-term AE and discontinuations by eligible dose; population-specific exposure/interactions and denominators
Conditions for verification: Distinguish direct information in the same population/exposure from unverified extensions.
Requirement and applicability: Supplementary; required for the corresponding extended claims about long-term or special-population safety
Application exceptions: Do not unconditionally require every rare-harm study for the current narrow HbA1c question.
Why this condition is needed: Needed to avoid guaranteeing safety in all populations from some brief observations.
Referenced methods: M19 §19.1.2–19.2.4; internal application; Chamgap’s own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied

N35 · Is the actual scope of funding, product provision and COI known?

Required materials and conditions: Report-specific funding, product provision, author relationships, COI declarations and original verification locations
Conditions for verification: Distinguish the level of disclosures/funding actually verified from materials not read in this review.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not automatically exclude a study or judge it free of bias solely on historical wording stating the presence or absence of COI.
Why this condition is needed: Required to avoid treating unverified funding as absent or as certification of independence.
Referenced methods: Chamgap’s own independence and attribution criteria. The official methodological sections used in this pilot do not warrant all these detailed items; the distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application.

N36 · Have historical full-text access and current summary reading been separated?

Required materials and conditions: Historical access_level/location by report; actual access dates; current local locations/values/SHA; external access unattempted
Conditions for verification: Link reading badges to the actual retained citations and keep unread external materials separate.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: If a report has no date field, leave it null; the global verified_date is a separate review date.
Why this condition is needed: Required to avoid retroactively treating retained statements of PDF access as full-text reading in this review.
Referenced methods: M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

N37 · Have ?/null values and no_human_study=true been preserved unchanged?

Required materials and conditions: Original ?/null score; B/S; nulls on the subsequent 5 axes; bounded human scope; related studies true
Conditions for verification: Separate the scope expressed by the original verdict/gate from the statuses of the new criteria.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not alter the original false/true/null values for convenience or convert them to a score of 0 or a new criterion-fulfillment rate.
Why this condition is needed: Required to avoid treating the historical calculator gate as absence of all human studies or as a new efficacy grade.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M04 §4.5, §4.6.3; the limits of the current data conversion follow the user’s scope and internal design; M08 §8.2.2, M15 §15.3.1; internal application

N38 · Have server_deployed and actual deployment in this work been distinguished?

Required materials and conditions: Original server_deployed/server_write_performed/first_published_scope; current local preparation
Conditions for verification: Separate the original metadata values/scope from the current local conversion and absence of public deployment.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Do not arbitrarily reconcile the original server_deployed=true and server_write=false.
Why this condition is needed: Required to avoid treating historical deployment metadata as evidence of site publication in this work.
Referenced methods: M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

N39 · Does the HbA1c table also answer questions about clinical events and improvements in quality of life?

Required materials and conditions: Boundary between the selected HbA1c question and separate questions about complications, quality of life, mortality, duration/dose
Conditions for verification: Separate the directly selected endpoint from additional questions extending beyond it.
Requirement and applicability: Supplementary; required for extended claims about clinical events, duration and dose
Application exceptions: Do not make clinical-event trials an unconditional requirement for the numerical HbA1c question.
Why this condition is needed: Required to avoid extending a numerical surrogate outcome to benefits in clinical events.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; adapting outcomes to each question is internally designed; M03 §3.2.1–3.2.4; details concerning dose, duration and effect modification are internally designed; M03 §3.2.4; internal boundaries for extensions

N40 · What changes when new direct results, full texts or corrections are acquired?

Required materials and conditions: Original identity/dates; original values before/after; corrections/retractions; criterion versions; update links
Conditions for verification: Explicitly link update triggers, required materials and affected items/preservation of history.
Requirement and applicability: Required (selected sole-added-biotin/HbA1c comparison)
Application exceptions: Adding new materials is separate from amending criteria/reaching a new verdict and from deployment; do not exceed the current authorized scope.
Why this condition is needed: Required to avoid making the current table a fixed truth or an automatic efficacy upgrade.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed; M04 §4.5, §4.6.3; the limits of the current data conversion follow the user’s scope and internal design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility criteria and reasons for changes, and distinguish variations in the intervention.
Extent of review: Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish and link studies and reports, and do not omit a study solely because its outcomes are not reported.
Extent of review: Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Hold the outcome and effect of interest fixed, then assess randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Questions about harms may require designs, populations and follow-up different from efficacy questions. Case reports do not establish incidence.
Extent of review: Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work

What the statuses mean

Partly verified: Some related materials/identity/historical information are available, but gaps remain in direct comparisons, plans, access and harms
Unverified: The actual materials required for the selected direct comparison could not be verified within the retained scope; this does not mean no effect or 0 studies
Review incomplete: Comparison against original sources/search was not performed within the authorized scope
Not reported: A scoped status indicating that the item is not stated in the specific material/section that was read
Inaccessible: Used only for materials for which access was actually attempted and failed. Not assigned to the clinical materials in this work
Insufficient evidence for this criterion: Used only when relevant studies within a defined scope have been reviewed and the evidence is insufficient to answer the criterion. Not applied to all items in this work
Not applicable: The extension requiring clinical events beyond HbA1c does not apply; not a substitute for Unverified
Conflicting information: The conflict between completer and flowchart denominators in the same report is preserved; no new calculation or correction
Met: Verification of the stated preservation/boundary, distinction and linkage criteria; not new direct HbA1c efficacy evidence, full-text reading or safety certification

Change history

2026-11-03 · Public page/material version 1.0

Public-facing display and data were created from the existing 40 items. No new clinical search, change in verification status or scoring was performed.

The stored-material review date (2026-10-05) and original evidence cut-off (2026-09-15) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which biotin, population and HbA1c comparison does the question concern?

Current findings: The selected question asks whether oral biotin as the sole added active ingredient in adults with T2D lowers HbA1c at a prespecified follow-up compared with placebo, no supplement or usual care under identical background treatment. subclaims is an empty list.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: This verifies the boundary; it does not establish efficacy or conclude that studies are absent worldwide.
Reason for missing information: This verifies the boundary; it does not establish efficacy or conclude that studies are absent worldwide.
Required materials and conditions: Adults with T2D · Oral biotin as the sole addition · Comparator with identical background conditions · Between-group HbA1c result at a prespecified time point
Materials to obtain first: Adults with T2D · Oral biotin as the sole addition · Comparator with identical background conditions · Between-group HbA1c result at a prespecified time point
Further research: For each source, compare the direct comparison results that match this question and the reasons for any mismatch.
Remaining uncertainty: This verifies the boundary; it does not establish efficacy or conclude that studies are absent worldwide.
Conditions for verification: Link the current original effect wording to the actual inclusion/exclusion boundaries and original pointers.
Why this condition is needed: Needed to avoid combining the ingredient as a whole or all glycemic markers into a single result.
Application exceptions: Type 1/gestational/healthy populations, confirmed deficiency correction, topical/injectable routes and concurrent changes in chromium are separate.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed

Related sources S01 S02 S04 S05 S10 S11 S15

N02 · Does common metformin treatment exclude a comparison of a sole added ingredient?

Current findings: S11 is a candidate in which only biotin was added to the common treatment of metformin 500 mg/day in both arms, so it is not excluded because of concomitant treatment. The endpoint actually verified is not HbA1c.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: This verifies the preservation of common-treatment information; it does not mean that an actual eligible HbA1c comparison has been obtained.
Reason for missing information: This verifies the preservation of common-treatment information; it does not mean that an actual eligible HbA1c comparison has been obtained.
Required materials and conditions: Background treatment in both arms, added ingredients, arm-specific changes/rescue treatment and the actual effect of interest
Materials to obtain first: Background treatment in both arms, added ingredients, arm-specific changes/rescue treatment and the actual effect of interest
Further research: Compare results in which only biotin differs under identical background treatment, along with changes in diabetes medications.
Remaining uncertainty: This verifies the preservation of common-treatment information; it does not mean that an actual eligible HbA1c comparison has been obtained.
Conditions for verification: Distinguish the difference in added ingredients from common treatment and link this distinction to endpoint eligibility.
Why this condition is needed: Common treatment must be distinguished from active ingredients that change concurrently.
Application exceptions: A comparison of biotin as the sole addition is not excluded merely because it is described as concomitant treatment.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application

Related sources S11

N03 · Are the chemical form, origin and manufacturer of the directly eligible product known?

Current findings: exact_chemical_form and manufacturing_origin have null value entries/not_verified. source_part also leaves the chemical form, origin and manufacturer of the eligible preparation unverified.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The product identity for a directly eligible HbA1c comparison could not be verified. Products from other trials are not substituted.
Reason for missing information: The product identity for a directly eligible HbA1c comparison could not be verified. Products from other trials are not substituted.
Required materials and conditions: Exact chemical form, origin, manufacturer and documentation verifying the active ingredient
Materials to obtain first: Exact chemical form, origin, manufacturer and documentation verifying the active ingredient
Further research: Obtain and link the original product documentation and manufacturing specifications for the eligible result.
Remaining uncertainty: The product identity for a directly eligible HbA1c comparison could not be verified. Products from other trials are not substituted.
Conditions for verification: Separate verified values for the directly eligible product from null values and reasons for nonverification.
Why this condition is needed: Needed to avoid filling in the identity of an eligible HbA1c regimen with a product from another study.
Application exceptions: Naming biotin in the question does not verify the chemical form of the actual preparation.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed

Related sources S01 S02 S04 S11 S15

N04 · Are tablet/capsule form, excipients, brand, batch and purity verified?

Current findings: tablet_or_capsule, excipients, brand and batch_purity all have null values/not_verified. An oral product with a sole active ingredient is the question boundary, not the specifications of an actual eligible product.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Beyond the shared ingredient name, no direct information on formulation, excipients or quality is available.
Reason for missing information: Beyond the shared ingredient name, no direct information on formulation, excipients or quality is available.
Required materials and conditions: Formulation, excipients, brand, batch/purity and other added active ingredients
Materials to obtain first: Formulation, excipients, brand, batch/purity and other added active ingredients
Further research: Compare the preparation specifications and batch documentation for the eligible comparison.
Remaining uncertainty: Beyond the shared ingredient name, no direct information on formulation, excipients or quality is available.
Conditions for verification: Identify the actual locations verifying the eligible formulation and composition/quality, or mark them as unverified.
Why this condition is needed: Needed to avoid claiming identical composition and quality based solely on a product name.
Application exceptions: Specifications of a combination product are not transferred as verification of a sole-active product.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed

Related sources S01 S02 S04 S11 S15

N05 · What are the eligible biotin dose, frequency and total exposure?

Current findings: dose, frequency, dietary_biotin and concurrent_supplements have null values/not_verified for the directly eligible comparison. S11's 5 mg 2 times daily is the exposure in a candidate study of another endpoint.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The eligible dose was not inferred from S11, chromium-combination products or assay-interference materials.
Reason for missing information: The eligible dose was not inferred from S11, chromium-combination products or assay-interference materials.
Required materials and conditions: Eligible dose/frequency, dietary biotin, concurrent supplements and actual exposure
Materials to obtain first: Eligible dose/frequency, dietary biotin, concurrent supplements and actual exposure
Further research: Link the relevant product, dose, frequency and dietary/supplement records to the eligible result.
Remaining uncertainty: The eligible dose was not inferred from S11, chromium-combination products or assay-interference materials.
Conditions for verification: Explain what is verified and what is missing about the actual dose and total exposure linked to the selected result.
Why this condition is needed: Needed to avoid using quantities from adjacent FPG studies or safety cases as an HbA1c regimen.
Application exceptions: Do not arbitrarily convert values expressed in mg, µmol and µg at different source locations into mass equivalents.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed

Related sources S01 S02 S05 S06 S11

N06 · Have the treatment duration and HbA1c follow-up time been specified?

Current findings: treatment_duration and followup_time have null values/not_verified. S11 used 4 weeks of biotin treatment followed by 2 weeks of observation off biotin, while S05 used a combination product for 90 days; neither fills in the eligible HbA1c duration.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The eligible duration and time point are unverified; this is not a conclusion that the treatment has no effect because its duration is short or long.
Reason for missing information: The eligible duration and time point are unverified; this is not a conclusion that the treatment has no effect because its duration is short or long.
Required materials and conditions: Actual treatment duration, prespecified follow-up time and separate post-discontinuation time point
Materials to obtain first: Actual treatment duration, prespecified follow-up time and separate post-discontinuation time point
Further research: Compare the direct comparison's plan, treatment duration and results at each follow-up time point together.
Remaining uncertainty: The eligible duration and time point are unverified; this is not a conclusion that the treatment has no effect because its duration is short or long.
Conditions for verification: Link the eligible treatment duration and prespecified HbA1c follow-up to the original plan/results.
Why this condition is needed: Needed to avoid transferring FPG at 4/6 weeks or a combination product at 90 days into the same HbA1c time point.
Application exceptions: Do not arbitrarily adopt a common minimum treatment duration.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed

Related sources S05 S11

N07 · Are confirmed T2D diagnosis, baseline HbA1c and disease duration verified?

Current findings: The question concerns adults with T2D, but diagnostic_criteria, baseline_HbA1c and disease_duration have null values for the directly eligible comparison. Materials on other populations are retained, with direct attribution restricted.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: An adjacent study recording baseline glycated hemoglobin is distinct from the target direct follow-up HbA1c comparison.
Reason for missing information: An adjacent study recording baseline glycated hemoglobin is distinct from the target direct follow-up HbA1c comparison.
Required materials and conditions: Diagnostic criteria, age, baseline HbA1c, disease duration and population composition
Materials to obtain first: Diagnostic criteria, age, baseline HbA1c, disease duration and population composition
Further research: Compare recruitment, diagnosis, baseline tables and population composition for the eligible result.
Remaining uncertainty: An adjacent study recording baseline glycated hemoglobin is distinct from the target direct follow-up HbA1c comparison.
Conditions for verification: Link the actual eligible population/baseline composition to the unverified items.
Why this condition is needed: Needed to avoid filling in the actual baseline status of the eligible sample from the population label alone.
Application exceptions: Type 1, gestational and drug-induced diabetes, prediabetes and healthy populations are retained as separate questions.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed

Related sources S01 S02 S04 S10 S11

N08 · Have observations of low biotin been recast as confirmed deficiency correction?

Current findings: baseline_biotin and deficiency_assay have null values for the eligible comparison. The original KO explicitly states that observations of low circulating biotin were not recast as a trial treating confirmed deficiency.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The exclusion/inclusion boundaries were preserved, but the biotin status of the actual eligible population remains unverified.
Reason for missing information: The exclusion/inclusion boundaries were preserved, but the biotin status of the actual eligible population remains unverified.
Required materials and conditions: baseline_biotin, deficiency_assay, deficiency definition and eligible status
Materials to obtain first: baseline_biotin, deficiency_assay, deficiency definition and eligible status
Further research: Link the deficiency definition/assay to the direct HbA1c results for each relevant population.
Remaining uncertainty: The exclusion/inclusion boundaries were preserved, but the biotin status of the actual eligible population remains unverified.
Conditions for verification: Separate the status verified by the original source from the level of diagnosis that remains unverified.
Why this condition is needed: Needed to distinguish blood-level observations, unreported status and treatment of confirmed deficiency.
Application exceptions: Unreported status is not presumed normal, and a trial is not described as treating deficiency solely because low levels were observed.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed

Related sources S01 S02 S04

N09 · Were between-group HbA1c changes distinguished from other glycemic outcomes?

Current findings: Priority is given to the between-group HbA1c change difference (%p), and an appropriately adjusted between-group endpoint contrast is separate. The original crux/content block and facets rule out substitution with FPG, PPG or other metabolic markers.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: This verifies the endpoint boundary; it does not mean that a direct estimate has been obtained.
Reason for missing information: This verifies the endpoint boundary; it does not mean that a direct estimate has been obtained.
Required materials and conditions: Prespecified between-group HbA1c change difference in %p, adjusted endpoint contrast and measurement/analysis definitions
Materials to obtain first: Prespecified between-group HbA1c change difference in %p, adjusted endpoint contrast and measurement/analysis definitions
Further research: Compare the original plan with the change/endpoint estimates in the actual HbA1c tables.
Remaining uncertainty: This verifies the endpoint boundary; it does not mean that a direct estimate has been obtained.
Conditions for verification: Attribute observations to the selected endpoint, unit, time point and analysis.
Why this condition is needed: Needed to avoid interpreting FPG/PPG, insulin, HOMA-IR, fructosamine or Hb as HbA1c.
Application exceptions: Do not automatically equate an adjusted endpoint contrast with a change difference.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

Related sources S01 S02 S04 S11

N10 · Are the HbA1c assay method and red-cell-related factors verified?

Current findings: HbA1c_assay, HbA1c_interference, anemia_RBC_lifespan, transfusion_hemoglobin_variant and renal_function have null values/not_verified.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Interference in the assay itself or between-arm differences in anemia could not be verified within the scope of the retained materials in this review.
Reason for missing information: Interference in the assay itself or between-arm differences in anemia could not be verified within the scope of the retained materials in this review.
Required materials and conditions: HbA1c assay, interference, anemia/RBC lifespan, transfusion/Hb variants and renal function
Materials to obtain first: HbA1c assay, interference, anemia/RBC lifespan, transfusion/Hb variants and renal function
Further research: Compare the assay principles, validation materials and baseline hematological/renal records for the eligible result.
Remaining uncertainty: Interference in the assay itself or between-arm differences in anemia could not be verified within the scope of the retained materials in this review.
Conditions for verification: Explain the actual assay method and arm-specific measurement conditions for the selected HbA1c outcome, and what remains unverified.
Why this condition is needed: Needed to distinguish changes in measured values from assay/red-cell conditions.
Application exceptions: Biotin interference in specific immunoassays is not generalized to all HbA1c methods.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; design considerations in M19 §19.2.2–19.2.4; detailed confounding records are internally designed

Related sources S01 S02 S04 S06 S07 S11

N11 · Is there an eligible between-group HbA1c estimate for biotin alone?

Current findings: between_group_effect, P and CI have null values for the directly eligible comparison. The assessment's direct_eligible_human_result_verified=false is a bounded gate for the fixed question. related_human_studies_exist=true is also retained.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Positive combination-product and FPG results are not substituted, and null values are not converted to 0.
Reason for missing information: Positive combination-product and FPG results are not substituted, and null values are not converted to 0.
Required materials and conditions: Directly eligible between-group HbA1c effect, follow-up time point, denominator and original result location
Materials to obtain first: Directly eligible between-group HbA1c effect, follow-up time point, denominator and original result location
Further research: Verify the between-group effect and its definition/time point in the eligible original result.
Remaining uncertainty: Positive combination-product and FPG results are not substituted, and null values are not converted to 0.
Conditions for verification: Link the direct estimate or an explicit gap within the currently verified scope.
Why this condition is needed: Needed to distinguish the existence of related human studies from obtaining a direct result for this question.
Application exceptions: Failure to verify a direct result is not described as an effect of 0 or an absence of human studies worldwide.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.5, §4.6.3; limits on the current material conversion follow the user's scope and internal design; M08 §8.2.2, M15 §15.3.1; internal application

Related sources S01 S02 S04 S05 S11 S15

N12 · Can the effect magnitude be interpreted using CI, P and MCID?

Current findings: CI, P and MCID all have null values/not_verified for the eligible HbA1c comparison. P=.03 for the chromium-combination product is not used to construct an interval or importance assessment for biotin alone.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: This is nonverification of the source data, not evidence of an unimportant effect, a definitive finding of imprecision or evidence of equivalence.
Reason for missing information: This is nonverification of the source data, not evidence of an unimportant effect, a definitive finding of imprecision or evidence of equivalence.
Required materials and conditions: Direct effect, confidence interval, variance, denominator and justified importance threshold
Materials to obtain first: Direct effect, confidence interval, variance, denominator and justified importance threshold
Further research: Compare the direct result's estimate, CI and basis for the MCID together.
Remaining uncertainty: This is nonverification of the source data, not evidence of an unimportant effect, a definitive finding of imprecision or evidence of equivalence.
Conditions for verification: Distinguish reported direct intervals/importance thresholds from the reasons interpretation is not possible.
Why this condition is needed: Needed to avoid equating a P value with clinical importance or precision.
Application exceptions: Do not arbitrarily set a minimum sample size, number of trials or numerical HbA1c importance threshold.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M15 §15.3.1–15.3.3; internal application

Related sources S05

N13 · Are the allocation, completion, analysis and ITT/PP denominators linked?

Current findings: randomized_n, completed_n, analysis_n and ITT_PP have null values for the directly eligible comparison. S11's 60 allocated participants, 28 and 26 completers by arm, and 60 participants in the flowchart are records for other endpoints.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: An unspecified analysis in the original source is not filled in as ITT or as an HbA1c analysis of all participants.
Reason for missing information: An unspecified analysis in the original source is not filled in as ITT or as an HbA1c analysis of all participants.
Required materials and conditions: Direct randomized/completed/analysis n, ITT/PP and reasons for/handling of missing data
Materials to obtain first: Direct randomized/completed/analysis n, ITT/PP and reasons for/handling of missing data
Further research: For each eligible result, compare the recruitment→allocation→completion→analysis flow and handling of missing data.
Remaining uncertainty: An unspecified analysis in the original source is not filled in as ITT or as an HbA1c analysis of all participants.
Conditions for verification: Show the actual denominator and handling for the relevant HbA1c outcome, or mark them as unverified.
Why this condition is needed: Needed to avoid using allocation or completion counts from another endpoint as HbA1c denominators.
Application exceptions: Do not sum n across different reports or arbitrarily reconcile flowchart conflicts.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

Related sources S11

N14 · Are allocation, concealment and baseline balance known for the direct HbA1c result?

Current findings: The retained evidence reports adjacent designs, including randomized blinded studies in S02/S04 and a single-center computer-randomized open-label trial in S11. The link between a directly eligible HbA1c result and its design is unverified.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The reference to trial_families.json in evidence does not mean that the file was read in this review.
Reason for missing information: The reference to trial_families.json in evidence does not mean that the file was read in this review.
Required materials and conditions: Actual eligible comparison design, randomized/nonrandomized allocation, concealment and baseline balance
Materials to obtain first: Actual eligible comparison design, randomized/nonrandomized allocation, concealment and baseline balance
Further research: Compare the protocol/allocation documents and baseline tables for the direct comparison.
Remaining uncertainty: The reference to trial_families.json in evidence does not mean that the file was read in this review.
Conditions for verification: Distinguish the verified design information for the selected result from the scope that remains unverified.
Why this condition is needed: Needed to avoid transferring a description of an adjacent randomized study as verification of the design for the selected HbA1c result.
Application exceptions: An unverified design is not labeled as crossover/cluster inapplicability or an automatic failure on bias.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M08 §8.1–8.2.3; internal application

Related sources S02 S04 S11

N15 · Are actual adherence, diabetes medication changes, diet and exercise known?

Current findings: adherence, background_diabetes_medication, medication_change_rescue and diet_exercise have null values/not_verified for the directly eligible comparison. These are separate verification items from the nominal common metformin exposure in S11.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Concurrent changes/handling needed for an actual incremental-effect analysis were not filled in solely from a nominal regimen in an adjacent study.
Reason for missing information: Concurrent changes/handling needed for an actual incremental-effect analysis were not filled in solely from a nominal regimen in an adjacent study.
Required materials and conditions: adherence, background meds, rescue/change, diet/exercise and handling in the analysis
Materials to obtain first: adherence, background meds, rescue/change, diet/exercise and handling in the analysis
Further research: Link adherence, rescue-treatment and arm-specific change records for the eligible original result.
Remaining uncertainty: Concurrent changes/handling needed for an actual incremental-effect analysis were not filled in solely from a nominal regimen in an adjacent study.
Conditions for verification: Explain arm-specific concurrent changes and adherence in the eligible comparison, and the gaps.
Why this condition is needed: Needed to separate concurrent changes from biotin's contribution.
Application exceptions: Verify the actual effect of interest and the handling methods rather than requiring all changes to be identical.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application

Related sources S11

N16 · Were the planned HbA1c outcome, analysis and time points compared with what was reported?

Current findings: S13/S14 are registry shells, and S15 is an indexed excerpt/shell. The historical limitation that some registry record texts, histories, protocols and SAPs could not be adequately obtained is explicitly stated in KO.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Having a registration number/link does not mean that the prespecified HbA1c plan has been verified. External lookups in this review: 0.
Reason for missing information: Having a registration number/link does not mean that the prespecified HbA1c plan has been verified. External lookups in this review: 0.
Required materials and conditions: Registry record text, history, protocol, SAP, actual results and reasons for changes
Materials to obtain first: Registry record text, history, protocol, SAP, actual results and reasons for changes
Further research: Compare the eligible candidate's registry history and original plan with the actual results.
Remaining uncertainty: Having a registration number/link does not mean that the prespecified HbA1c plan has been verified. External lookups in this review: 0.
Conditions for verification: Identify the locations showing what was actually compared and the plans/time points not compared.
Why this condition is needed: Needed to distinguish a registry shell from verification of the original plan.
Application exceptions: Failure to obtain material is not recast as confirmed nonregistration or selective reporting.
Referenced methods: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current material conversion follow the user's scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S13 S14 S15

N17 · Were Maebashi's fasting-glucose findings transferred to HbA1c?

Current findings: F01/S01 concern fasting-glucose and circulating-biotin results, not between-group HbA1c results. The original KO did not recast the observed low levels as a trial treating confirmed deficiency.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The publisher_full_pdf level reported at the time does not mean an external PDF was read now. Specific numbers are referenced separately in numeric_evidence and were not read this time.
Reason for missing information: The publisher_full_pdf level reported at the time does not mean an external PDF was read now. Specific numbers are referenced separately in numeric_evidence and were not read this time.
Required materials and conditions: Maebashi’s actual population, ingredient, comparator, time point and endpoint, and whether a between-group HbA1c result exists
Materials to obtain first: Maebashi’s actual population, ingredient, comparator, time point and endpoint, and whether a between-group HbA1c result exists
Further research: Verify S01’s actual HbA1c results/plans during an authorized update.
Remaining uncertainty: The publisher_full_pdf level reported at the time does not mean an external PDF was read now. Specific numbers are referenced separately in numeric_evidence and were not read this time.
Conditions for verification: Link the originally retained S01 results to the reason for exclusion from direct evidence.
Why this condition is needed: Needed to distinguish the existence of biotin-only studies from an eligible HbA1c result.
Application exceptions: Do not reclassify observations of low circulating biotin or the long-term combination arm as a sole-biotin comparison treating confirmed deficiency.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

Related sources S01

N18 · Is Báez-Saldaña’s baseline glycated hemoglobin a follow-up effect?

Current findings: F02/S02/S03 contain baseline glycated hemoglobin and enzyme/other metabolic-marker data; an eligible between-group HbA1c change/endpoint effect was not verified. The evidence field reports a randomized, blinded 28-day protocol after a cross-sectional phase.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Verifying a study’s existence and baseline values does not establish a direct follow-up effect.
Reason for missing information: Verifying a study’s existence and baseline values does not establish a direct follow-up effect.
Required materials and conditions: Baseline and follow-up HbA1c; the 28-day comparison; table/analysis definitions
Materials to obtain first: Baseline and follow-up HbA1c; the 28-day comparison; table/analysis definitions
Further research: Verify the HbA1c follow-up contrast, denominator and time point in the original results tables.
Remaining uncertainty: Verifying a study’s existence and baseline values does not establish a direct follow-up effect.
Conditions for verification: Distinguish S02’s baseline/other results from the unverified eligible effect.
Why this condition is needed: Needed to avoid misreading baseline characteristics as an estimate of between-group change.
Application exceptions: Do not recast enzyme or metabolic markers as between-group HbA1c follow-up results.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

Related sources S02 S03

N19 · Were the location-specific values in the µmol/day erratum preserved?

Current findings: KO preserves the correction of 6.14 µmol/day to 61.4 µmol/day at several daily-dose locations and the 20.5 µmol/day notation at another specified location. S02/S03 belong to one study-and-erratum family.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The retained erratum summary was read, but the original bytes and each detailed location in the external erratum were not read this time. New conversions/corrections: 0.
Reason for missing information: The retained erratum summary was read, but the original bytes and each detailed location in the external erratum were not read this time. New conversions/corrections: 0.
Required materials and conditions: Relevant locations in the original text and erratum; the 6.14/61.4/20.5 µmol notations; the relationship between versions
Materials to obtain first: Relevant locations in the original text and erratum; the 6.14/61.4/20.5 µmol notations; the relationship between versions
Further research: Verify the original bytes, locations and versions of the original text and erratum, and update each exposure record.
Remaining uncertainty: The retained erratum summary was read, but the original bytes and each detailed location in the external erratum were not read this time. New conversions/corrections: 0.
Conditions for verification: Link the location-specific correction notations and remaining identity/interpretation limitations to the original text.
Why this condition is needed: Needed to avoid creating a new dose by ignoring the erratum or standardizing the values to a single value.
Application exceptions: Do not turn unclear locations or units into arbitrary mg conversions or personal prescriptions.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

Related sources S02 S03

N20 · Are Revilla-Monsalve’s lipid/glucose results HbA1c?

Current findings: F03/S04 is a 28-day randomized, blinded placebo comparison with lipid, fasting-glucose and insulin results. Between-group HbA1c results were not verified in the original material.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The current URL is a PubMed bibliographic record/abstract. Do not present historical access, including author text, as current reading of the full text at that URL.
Reason for missing information: The current URL is a PubMed bibliographic record/abstract. Do not present historical access, including author text, as current reading of the full text at that URL.
Required materials and conditions: S04’s actual lipid, FPG and insulin results, and eligible between-group HbA1c results
Materials to obtain first: S04’s actual lipid, FPG and insulin results, and eligible between-group HbA1c results
Further research: Verify S04’s original plan/results tables for the presence of eligible HbA1c.
Remaining uncertainty: The current URL is a PubMed bibliographic record/abstract. Do not present historical access, including author text, as current reading of the full text at that URL.
Conditions for verification: Link the other endpoints in the original record to the reason for exclusion from direct HbA1c evidence.
Why this condition is needed: Needed to avoid substituting changes in other metabolic markers for the selected endpoint.
Application exceptions: Do not establish an endpoint match solely from the 28-day randomized placebo design.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

Related sources S04

N21 · What were the exposure and off-treatment periods in Devi/Ranjani?

Current findings: S11 allocated 60 participants, 30 per arm, with metformin 500 mg/day for 6 weeks as common treatment and biotin 5 mg 2 times daily for 4 weeks followed by 2 weeks off. The verified weekly endpoints are FPG/PPG.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: This verifies preservation of the nominal exposure, not an actual eligible HbA1c result or a sustained long-term effect.
Reason for missing information: This verifies preservation of the nominal exposure, not an actual eligible HbA1c result or a sustained long-term effect.
Required materials and conditions: Biotin 5 mg 2 times daily for 4 weeks; 2 weeks off; metformin 500 mg/day for 6 weeks in both arms; actual endpoints
Materials to obtain first: Biotin 5 mg 2 times daily for 4 weeks; 2 weeks off; metformin 500 mg/day for 6 weeks in both arms; actual endpoints
Further research: Verify administration, discontinuation and the presence of HbA1c at each time point in the original plan/results.
Remaining uncertainty: This verifies preservation of the nominal exposure, not an actual eligible HbA1c result or a sustained long-term effect.
Conditions for verification: Link the retained exposure, common treatment and off-treatment period to the verified endpoints.
Why this condition is needed: Needed to preserve this candidate added-ingredient comparison without confusing duration and endpoints.
Application exceptions: Do not recast 4 weeks of use as 6 weeks of continuous exposure or HbA1c follow-up.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; details on dose, persistence and effect modification are internally designed

Related sources S11

N22 · Were the completer analyses by arm and the flowchart’s 60 participants both retained?

Current findings: S11’s results text/tables present completer analyses of control 28/biotin 26 participants, while the flowchart shows 60 completers. KO preserves both and explicitly states that Hb was not read as HbA1c.
Verification status: Conflicting information
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Who was omitted or which denominator is correct was not resolved within the scope of the original retained material. These counts are not used as the eligible HbA1c analysis n either.
Reason for missing information: Who was omitted or which denominator is correct was not resolved within the scope of the original retained material. These counts are not used as the eligible HbA1c analysis n either.
Required materials and conditions: S11 results text/tables: control 28 and biotin 26 participants; flowchart: 60 completers; analysis definitions
Materials to obtain first: S11 results text/tables: control 28 and biotin 26 participants; flowchart: 60 completers; analysis definitions
Further research: Compare the original text, flowchart, corrections and analysis specifications to verify the reason for the denominator discrepancy.
Remaining uncertainty: Who was omitted or which denominator is correct was not resolved within the scope of the original retained material. These counts are not used as the eligible HbA1c analysis n either.
Conditions for verification: Preserve conflicting denominators within the same report and the limits on attributing results/endpoints.
Why this condition is needed: Needed to avoid arbitrarily reconciling the conflicting completion/analysis denominators into the selected HbA1c sample.
Application exceptions: Do not read blood-test Hb as HbA1c. Recalculations of the original numbers/changes to the flowchart: 0.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

Related sources S11

N23 · Are week 4 P=.001 and week 6 P=.087 the same result?

Current findings: In the same S11, the week 4 FPG endpoint comparison has nominal P=.001, and week 6 after discontinuation has P=.087. These are FPG results at different time points, not HbA1c.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Nonsignificance does not establish equivalence or an exactly null effect. No new CI/effect calculations were performed.
Reason for missing information: Nonsignificance does not establish equivalence or an exactly null effect. No new CI/effect calculations were performed.
Required materials and conditions: S11 FPG endpoint comparison: time point, whether biotin had been stopped, P, and whether the endpoint was HbA1c
Materials to obtain first: S11 FPG endpoint comparison: time point, whether biotin had been stopped, P, and whether the endpoint was HbA1c
Further research: Separately verify the prespecified plan, between-group estimates/intervals at each time point and the effect of discontinuation.
Remaining uncertainty: Nonsignificance does not establish equivalence or an exactly null effect. No new CI/effect calculations were performed.
Conditions for verification: Retain the differences in results and exposure at the two time points together with the limits on direct attribution.
Why this condition is needed: Needed to avoid selecting only the positive time point or treating nonsignificance as equivalence.
Application exceptions: Do not transfer FPG results at different time points to an HbA1c effect or turn nonsignificance into an effect of 0.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M15 §15.3.1–15.3.3; internal application; M03 §3.2.1–3.2.4; details on dose, persistence and effect modification are internally designed

Related sources S11

N24 · Were 447 participants and P=.03 used as a biotin-only HbA1c result?

Current findings: Albarracin S05 reports 447 participants, a combination of chromium 600 µg+biotin 2 mg/day for 90 days versus placebo, and a between-group HbA1c-change P=.03. The positive finding is preserved and is not attributed to biotin alone.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The direct sole-biotin effect size, CI and clinical importance cannot be filled in from this combination result.
Reason for missing information: The direct sole-biotin effect size, CI and clinical importance cannot be filled in from this combination result.
Required materials and conditions: S05: chromium 600 µg+biotin 2 mg/day for 90 days versus placebo; 447 participants; between-group HbA1c P=.03
Materials to obtain first: S05: chromium 600 µg+biotin 2 mg/day for 90 days versus placebo; 447 participants; between-group HbA1c P=.03
Further research: Separately verify an eligible HbA1c comparison in which only biotin differs against the same chromium background.
Remaining uncertainty: The direct sole-biotin effect size, CI and clinical importance cannot be filled in from this combination result.
Conditions for verification: Link the combination-product results to the reason for exclusion from sole-biotin evidence.
Why this condition is needed: The positive HbA1c result must be preserved while limiting attribution because another ingredient also changed.
Application exceptions: The same background diabetes treatment does not isolate the incremental effects of chromium/biotin individually.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

Related sources S05

N25 · Were 348 participants and the active arm’s 226 participants counted as a different study/the total n?

Current findings: The related combination report’s 348 participants comprise active 226 and placebo 122 participants; 226 is not used as the total n. F04 conservatively groups possible overlap, and the S12 review is not added to its included studies.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The number of unique independent trials/total participants is unconfirmed; new sums/back-calculations: 0.
Reason for missing information: The number of unique independent trials/total participants is unconfirmed; new sums/back-calculations: 0.
Required materials and conditions: S05/S08/S13 and review S12: study families; 348=active 226/placebo 122; overlap relationships
Materials to obtain first: S05/S08/S13 and review S12: study families; 348=active 226/placebo 122; overlap relationships
Further research: Compare recruitment, periods and participant links across the relevant reports and registries.
Remaining uncertainty: The number of unique independent trials/total participants is unconfirmed; new sums/back-calculations: 0.
Conditions for verification: Distinguish verified families/unconfirmed overlaps and report-specific denominators.
Why this condition is needed: Needed to avoid double-counting original reports, follow-up reports, registries and reviews as replication trials or participants.
Application exceptions: Do not convert a possibly shared cohort into either confirmed independence or confirmed complete identity.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

Related sources S05 S08 S12 S13

N26 · Were Singer/Geohas’s sample and results verified?

Current findings: S09 is primary_index_only for a chromium-biotin combination pilot report. F05’s S14 registry linkage is provisional, and the exact study-to-report link is unconfirmed.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The historical scope did not yield result extraction beyond the retained title/index; new access to the original text this time: 0.
Reason for missing information: The historical scope did not yield result extraction beyond the retained title/index; new access to the original text this time: 0.
Required materials and conditions: S09 original text and results tables; actual study linkage to registry S14; sole/combination composition
Materials to obtain first: S09 original text and results tables; actual study linkage to registry S14; sole/combination composition
Further research: Compare the S09 original text with the S14 history and actual recruitment/results.
Remaining uncertainty: The historical scope did not yield result extraction beyond the retained title/index; new access to the original text this time: 0.
Conditions for verification: Identify the verified title/index and the unverified original results/registry linkage.
Why this condition is needed: Needed to distinguish bibliographic discovery from verification of eligible results.
Application exceptions: Do not establish a confirmed shared family or participant count when the registry-number linkage is provisional.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

Related sources S09 S14

N27 · Were type 1 HbA1c candidates transferred to T2D?

Current findings: F06/S10 is a biotin add-on-to-insulin study in type 1 diabetes and is not directly attributed to the adult T2D question. The historical PMC full access challenge/partial abstract level is preserved separately.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The PMC full text was not read this time, and results in the other population were not deleted.
Reason for missing information: The PMC full text was not read this time, and results in the other population were not deleted.
Required materials and conditions: S10’s actual type1 population, common insulin treatment and extraction level
Materials to obtain first: S10’s actual type1 population, common insulin treatment and extraction level
Further research: Verify direct T2D results separately and retain type1 data for a different question.
Remaining uncertainty: The PMC full text was not read this time, and results in the other population were not deleted.
Conditions for verification: Link S10’s actual population mismatch to the historical access limitations.
Why this condition is needed: Needed to avoid counting human studies in a population different from the question’s population as direct results.
Application exceptions: Do not delete data from other populations or use them as evidence that no human studies exist.
Referenced methods: M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

Related sources S10

N28 · Was GUTERRING excluded solely because its title mentions a combination?

Current findings: F08/S15 is a biotin-only arm candidate in an officially indexed pilot open-label randomized 4-arm design. KO records that it was not excluded solely because of the combination wording in the title, but direct T2D HbA1c results remain unverified.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: An indexed excerpt/shell does not constitute obtaining the complete registry plan/results.
Reason for missing information: An indexed excerpt/shell does not constitute obtaining the complete registry plan/results.
Required materials and conditions: NCT05832190’s actual 4 arms, biotin-only arm, population/follow-up HbA1c results and plan
Materials to obtain first: NCT05832190’s actual 4 arms, biotin-only arm, population/follow-up HbA1c results and plan
Further research: Verify the registry body/history, population, actual biotin-only arm results and HbA1c time points.
Remaining uncertainty: An indexed excerpt/shell does not constitute obtaining the complete registry plan/results.
Conditions for verification: Indicate separately the retention of the registry candidate and the lack of verified direct results.
Why this condition is needed: Needed to avoid omitting a potential biotin-only arm candidate solely on the basis of the title.
Application exceptions: Do not claim that an eligible T2D HbA1c result has been verified solely because a biotin-only arm exists.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S15

N29 · Is a review counted as an original trial or independent verification?

Current findings: S12 is a 2022 systematic review/meta-analysis serving as a literature map; the retained location is the HbA1c subsection/refs32–39. KO did not double-count the review, original papers, follow-up reports and registries.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: What was actually read this time was the stored bibliography and linked KO. The external review’s original text, the original bytes of its inclusion tables and its numbers were not read.
Reason for missing information: What was actually read this time was the stored bibliography and linked KO. The external review’s original text, the original bytes of its inclusion tables and its numbers were not read.
Required materials and conditions: The S12 review’s question, search cutoff, included studies/endpoints and links to original reports
Materials to obtain first: The S12 review’s question, search cutoff, included studies/endpoints and links to original reports
Further research: Compare the review’s inclusion tables with the original reports’ results and the overlap/sole-ingredient boundaries.
Remaining uncertainty: What was actually read this time was the stored bibliography and linked KO. The external review’s original text, the original bytes of its inclusion tables and its numbers were not read.
Conditions for verification: Distinguish the review’s role and the family/endpoint differences among its included original studies.
Why this condition is needed: Needed to avoid counting mixtures of endpoints/ingredients and repeated citations as independent results.
Application exceptions: Do not claim to have read the entire review/numeric files this time.
Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

Related sources S01 S02 S04 S05 S08 S09 S11 S12 S13

N30 · Do the discovery and access failure concerning Coggeshall constitute a negative result?

Current findings: F09/S16 is at the level of bibliographic discovery of a 1985 report. The population/eligible original between-group HbA1c results were not sufficiently verified, and the historical access_level is metadata_and_failed_full_text.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The failure at that time is not a failed access attempt this time. Do not count the candidate as a negative result.
Reason for missing information: The failure at that time is not a failed access attempt this time. Do not count the candidate as a negative result.
Required materials and conditions: S16’s actual original text, population, sole-biotin comparison, HbA1c follow-up and historical failure record
Materials to obtain first: S16’s actual original text, population, sole-biotin comparison, HbA1c follow-up and historical failure record
Further research: Verify the relevant original text, population and follow-up results during an authorized update.
Remaining uncertainty: The failure at that time is not a failed access attempt this time. Do not count the candidate as a negative result.
Conditions for verification: Separate the retained discovery/historical failure from the current unread status and the lack of verified eligible evidence.
Why this condition is needed: Needed to distinguish a candidate whose original text was not obtained from no effect.
Application exceptions: Do not use metadata_and_failed_full_text to represent a current failed-access action or worldwide study absence.
Referenced methods: M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

Related sources S16

N31 · Is the lack of verified direct evidence expressed as 0 studies worldwide?

Current findings: The original KO/assessment limits its statement to not having verified directly eligible results within the documented search scope. S17 WHO ICTRP was internal error/access_failed at the time; current external lookups/searches: 0.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Do not retroactively treat the original verified_date/evidence reference date, 9/15, as the current full-text reading date.
Reason for missing information: Do not retroactively treat the original verified_date/evidence reference date, 9/15, as the current full-text reading date.
Required materials and conditions: The 2026-09-15 original review/search scope, ICTRP failure and scope of this reading of retained material
Materials to obtain first: The 2026-09-15 original review/search scope, ICTRP failure and scope of this reading of retained material
Further research: Verify search records, unpublished studies/registries and correction coverage in an authorized update as a separate event.
Remaining uncertainty: Do not retroactively treat the original verified_date/evidence reference date, 9/15, as the current full-text reading date.
Conditions for verification: Link every expression of absence or lack of verification to its actual scope and date.
Why this condition is needed: Needed to distinguish a bounded gate from complete absence of literature.
Application exceptions: The 0 searches this time do not mean 0 studies. Historical selection_log/ZIP references do not constitute current acquisition.
Referenced methods: M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

Related sources S13 S14 S15 S16 S17

N32 · Was TSH/troponin interference generalized to interference with HbA1c itself?

Current findings: The retained NIH/FDA content concerns selected thyroid tests after a single 10 mg dose within 24 hours, selected TSH/NT-proBNP tests in 6 people receiving 10 mg/day for 1 week, and falsely low results in some troponin tests. It does not establish the same interference in every test/HbA1c method.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Do not present the original official extract as actual access to the official full text this time. Do not provide personal dosing, stopping or testing schedules.
Reason for missing information: Do not present the original official extract as actual access to the official full text this time. Do not provide personal dosing, stopping or testing schedules.
Required materials and conditions: NIH/FDA’s specific assays, populations, exposures and time points, with separate verification of the HbA1c assay
Materials to obtain first: NIH/FDA’s specific assays, populations, exposures and time points, with separate verification of the HbA1c assay
Further research: Separately verify validation for each relevant HbA1c method and data on biotin exposure/blood-sampling time points.
Remaining uncertainty: Do not present the original official extract as actual access to the official full text this time. Do not provide personal dosing, stopping or testing schedules.
Conditions for verification: Separate the assay/exposure scope of the retained safety material from the lack of verification for the selected HbA1c endpoint.
Why this condition is needed: Needed to avoid turning biotin interference into actual glycemic improvement or a risk for every test.
Application exceptions: Statements concerning specific TSH/NT-proBNP/troponin tests do not directly establish interference with an HbA1c assay.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; detailed distinctions are internally designed; M19 §19.2 design-specific harm questions; temporal-relationship details are internally designed; Chamgap’s own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied

Related sources S06 S07

N33 · Are the frequencies of nausea, loose stools and gastric irritation in S11 known?

Current findings: KO preserves nausea, loose stools and gastric irritation from the trial with common metformin treatment and states that the safety-analysis denominator is unclear. The stored summary read this time retains a reference to numeric_evidence N12 instead of specific event counts.
Verification status: Partly verified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The numeric file and original safety tables were not read this time. Do not elevate limited short-term experience involving another endpoint into long-term safety of sole-biotin add-on therapy.
Reason for missing information: The numeric file and original safety tables were not read this time. Do not elevate limited short-term experience involving another endpoint into long-term safety of sole-biotin add-on therapy.
Required materials and conditions: People with AE/events by arm; collection; exposure/follow-up; safety-analysis denominators; discontinuation
Materials to obtain first: People with AE/events by arm; collection; exposure/follow-up; safety-analysis denominators; discontinuation
Further research: Separately verify the original AE tables, collection methods and arm-specific denominators/discontinuations.
Remaining uncertainty: The numeric file and original safety tables were not read this time. Do not elevate limited short-term experience involving another endpoint into long-term safety of sole-biotin add-on therapy.
Conditions for verification: Link the retained symptoms to gaps in safety denominators/directly eligible exposure.
Why this condition is needed: Needed to distinguish the presence of symptoms from incidence rates or a guarantee of long-term safety.
Application exceptions: Do not calculate event rates or NNH from unclear safety denominators, or treat unreported data as 0.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; detailed distinctions are internally designed; M19 §19.2.2–19.2.4 design considerations; detailed confounding records are internally designed; M19 §19.1.2–19.2.4, M04 §4.6.3; internal application; Chamgap’s own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied

Related sources S11

N34 · Is there safety evidence for long-term use, pregnancy/lactation, children, hepatic/renal disease and concurrent use?

Current findings: The original safety_detail explicitly states that long-term add-on use in T2D, pregnancy, lactation, children, hepatic/renal disease, concurrent use and eligible dose-specific AE/discontinuations are unverified.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Unverified information does not establish either safety or harm, and no personal dosing instructions are created.
Reason for missing information: Unverified information does not establish either safety or harm, and no personal dosing instructions are created.
Required materials and conditions: Long-term AE and discontinuations by eligible dose; population-specific exposure/interactions and denominators
Materials to obtain first: Long-term AE and discontinuations by eligible dose; population-specific exposure/interactions and denominators
Further research: Separately verify long-term/population-specific harms and observation conditions for the same product and dose.
Remaining uncertainty: Unverified information does not establish either safety or harm, and no personal dosing instructions are created.
Conditions for verification: Distinguish direct information in the same population/exposure from unverified extensions.
Why this condition is needed: Needed to avoid guaranteeing safety in all populations from some brief observations.
Application exceptions: Do not unconditionally require every rare-harm study for the current narrow HbA1c question.
Referenced methods: M19 §19.1.2–19.2.4; internal application; Chamgap’s own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied

Related sources S06 S07 S11

N35 · Is the actual scope of funding, product provision and COI known?

Current findings: The funding fields of the 9 evidence items refer to trial_families.json for detailed verified and unverified information. The S11 location includes p106 COI, but the currently retained summary does not reproduce the specific disclosures.
Verification status: Unverified
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The existence of a referenced file or COI location does not mean its contents were read in this review. Do not infer the number of independent trials or lack of industry involvement.
Reason for missing information: The existence of a referenced file or COI location does not mean its contents were read in this review. Do not infer the number of independent trials or lack of industry involvement.
Required materials and conditions: Report-specific funding, product provision, author relationships, COI declarations and original verification locations
Materials to obtain first: Report-specific funding, product provision, author relationships, COI declarations and original verification locations
Further research: Verify original research funding/COI and product supply records by report.
Remaining uncertainty: The existence of a referenced file or COI location does not mean its contents were read in this review. Do not infer the number of independent trials or lack of industry involvement.
Conditions for verification: Distinguish the level of disclosures/funding actually verified from materials not read in this review.
Why this condition is needed: Required to avoid treating unverified funding as absent or as certification of independence.
Application exceptions: Do not automatically exclude a study or judge it free of bias solely on historical wording stating the presence or absence of COI.
Referenced methods: Chamgap’s own independence and attribution criteria. The official methodological sections used in this pilot do not warrant all these detailed items; the distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application.

Related sources S01 S02 S04 S05 S08 S09 S10 S11 S15 S16

N36 · Have historical full-text access and current summary reading been separated?

Current findings: What was actually read in this review consists of the exact retained Korean content, bibliography and structure/metadata, with the retained summaries’ locations/values/SHA. publisher_full_pdf, author_text, official_extract, shell and failure are historical records; external materials/referenced historical ZIP files have not been read in this review.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Each report’s historical access date is null because the source material contains no date; retain the review date 9/15 in a separate field. The existence of an external URL is not new acquisition.
Reason for missing information: Each report’s historical access date is null because the source material contains no date; retain the review date 9/15 in a separate field. The existence of an external URL is not new acquisition.
Required materials and conditions: Historical access_level/location by report; actual access dates; current local locations/values/SHA; external access unattempted
Materials to obtain first: Historical access_level/location by report; actual access dates; current local locations/values/SHA; external access unattempted
Further research: If new access is separately authorized, independently record the material/time/original bytes.
Remaining uncertainty: Each report’s historical access date is null because the source material contains no date; retain the review date 9/15 in a separate field. The existence of an external URL is not new acquisition.
Conditions for verification: Link reading badges to the actual retained citations and keep unread external materials separate.
Why this condition is needed: Required to avoid retroactively treating retained statements of PDF access as full-text reading in this review.
Application exceptions: If a report has no date field, leave it null; the global verified_date is a separate review date.
Referenced methods: M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

Related sources S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12 S13 S14 S15 S16 S17

N37 · Have ?/null values and no_human_study=true been preserved unchanged?

Current findings: Preserve the original ?, null score, B/S, nulls on the subsequent 5 axes, no_human_study=true and human_study_exists=false unchanged. The assessment’s scope is direct eligible HbA1c results, and related_human_studies_exist=true.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Blue in this table indicates verification of the stated preservation/boundary criteria; it does not establish a direct effect, constitute official methodological certification or represent a new verdict.
Reason for missing information: Blue in this table indicates verification of the stated preservation/boundary criteria; it does not establish a direct effect, constitute official methodological certification or represent a new verdict.
Required materials and conditions: Original ?/null score; B/S; nulls on the subsequent 5 axes; bounded human scope; related studies true
Materials to obtain first: Original ?/null score; B/S; nulls on the subsequent 5 axes; bounded human scope; related studies true
Further research: If direct evidence is added, consider a separate update that preserves the original values/reasons for change.
Remaining uncertainty: Blue in this table indicates verification of the stated preservation/boundary criteria; it does not establish a direct effect, constitute official methodological certification or represent a new verdict.
Conditions for verification: Separate the scope expressed by the original verdict/gate from the statuses of the new criteria.
Why this condition is needed: Required to avoid treating the historical calculator gate as absence of all human studies or as a new efficacy grade.
Application exceptions: Do not alter the original false/true/null values for convenience or convert them to a score of 0 or a new criterion-fulfillment rate.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M04 §4.5, §4.6.3; the limits of the current data conversion follow the user’s scope and internal design; M08 §8.2.2, M15 §15.3.1; internal application

Related sources

N38 · Have server_deployed and actual deployment in this work been distinguished?

Current findings: Preserve the original server_deployed=true, server_write_performed=false, deployed_at 2026-09-15 and initial snapshot scope. This work is a local table conversion, with 0 public site deployments.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: Do not certify the current actual publication status solely from the original metadata.
Reason for missing information: Do not certify the current actual publication status solely from the original metadata.
Required materials and conditions: Original server_deployed/server_write_performed/first_published_scope; current local preparation
Materials to obtain first: Original server_deployed/server_write_performed/first_published_scope; current local preparation
Further research: If actual publication is separately authorized, verify the production URL/display/links and record the event.
Remaining uncertainty: Do not certify the current actual publication status solely from the original metadata.
Conditions for verification: Separate the original metadata values/scope from the current local conversion and absence of public deployment.
Why this condition is needed: Required to avoid treating historical deployment metadata as evidence of site publication in this work.
Application exceptions: Do not arbitrarily reconcile the original server_deployed=true and server_write=false.
Referenced methods: M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design

Related sources

N39 · Does the HbA1c table also answer questions about clinical events and improvements in quality of life?

Current findings: The selected question concerns between-group numerical HbA1c results. The original assessment uses an S surrogate and does not upgrade it to an H clinical event/P functional endpoint.
Verification status: Not applicable
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: The criterion is not applicable because event studies are not required to complete this numerical table; this does not substitute for verification or nonverification of clinical-event benefits.
Reason for missing information: The criterion is not applicable because event studies are not required to complete this numerical table; this does not substitute for verification or nonverification of clinical-event benefits.
Required materials and conditions: Boundary between the selected HbA1c question and separate questions about complications, quality of life, mortality, duration/dose
Materials to obtain first: Boundary between the selected HbA1c question and separate questions about complications, quality of life, mortality, duration/dose
Further research: Review direct results and criteria separately for questions about events/long-term outcomes/dose.
Remaining uncertainty: The criterion is not applicable because event studies are not required to complete this numerical table; this does not substitute for verification or nonverification of clinical-event benefits.
Conditions for verification: Separate the directly selected endpoint from additional questions extending beyond it.
Why this condition is needed: Required to avoid extending a numerical surrogate outcome to benefits in clinical events.
Application exceptions: Do not make clinical-event trials an unconditional requirement for the numerical HbA1c question.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; adapting outcomes to each question is internally designed; M03 §3.2.1–3.2.4; details concerning dose, duration and effect modification are internally designed; M03 §3.2.4; internal boundaries for extensions

Related sources

N40 · What changes when new direct results, full texts or corrections are acquired?

Current findings: The original revision_triggers are new direct HbA1c results, full texts/registrations/SAPs, corrections/retractions, numerical/classification errors and new safety materials. Maintain the same ID/URL and the policy of retaining old/new/reason/source/date.
Verification status: Met
Materials actually read: Exactly preserved stored summaries: summary locations/values actually read; external full texts and older separate reference files not read in this review
Why unverified: No new search, calculation, update to the original verdict or public release was performed in this work.
Reason for missing information: No new search, calculation, update to the original verdict or public release was performed in this work.
Required materials and conditions: Original identity/dates; original values before/after; corrections/retractions; criterion versions; update links
Materials to obtain first: Original identity/dates; original values before/after; corrections/retractions; criterion versions; update links
Further research: Register separately authorized full texts, direct HbA1c results and corrections with their exact locations/values/hashes, then review the linked items again.
Remaining uncertainty: No new search, calculation, update to the original verdict or public release was performed in this work.
Conditions for verification: Explicitly link update triggers, required materials and affected items/preservation of history.
Why this condition is needed: Required to avoid making the current table a fixed truth or an automatic efficacy upgrade.
Application exceptions: Adding new materials is separate from amending criteria/reaching a new verdict and from deployment; do not exceed the current authorized scope.
Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed; M04 §4.5, §4.6.3; the limits of the current data conversion follow the user’s scope and internal design

Related sources